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A Study of Human Papillomavirus (HPV) Types in Young South African 




Human Papillomavirus (HPV) is the most common sexually transmitted 
infection. HPV infections are important in the pathogenesis of cervical 
cancer, the second most common cancer in women worldwide. 
Epidemiological data on HPV types demonstrate that the vaccine targeted 
HPV 16 and 18 are the most prevalent types found in cancer globally, while 
HPV types 6 and 11 are found in 90% of genital warts. However, there are 
significant geographic variations in the prevalence of less common 
genotypes. Data on HPV prevalence, type distribution, persistence and 
clearance in young South African women is limited and will provide 
justification for the introduction of vaccination. Therefore it is important that 
accurate determination of the prevalence of different HPV types in this 
country are known. HPV variants differ by 2% in the L1 gene and differ by up 
to 5% in the non-coding long control region (LCR). Therefore, the LCR is 
considered the most variable region in the entire HPV genome.  
 
For this M.Sc. thesis two studies were performed: 
 
 Genotyping of HPV from sexually-active HIV negative young women  
 Analysis of HPV variants isolated from South Africa couples. 
  
 
Genotyping of HPV from sexually-active HIV negative young women 
There is limited information on the prevalence of HPV and the HPV types 
infecting young South African women and this study aimed to determine the 












Cervico-vaginal lavage (CVL) specimens were collected at baseline and 
quarterly visits from sexually-active HIV negative women that were ≤30 years 
of age, participating in a HIV seroincidence study in KwaZulu Natal, South 
Africa. The Roche Linear Array HPV Genotyping assay was used to 
determine HPV types from 434 CVL specimens. An overall total of 434 CVL 
pellets were genotyped, this included 223 baseline specimens, 106 second 
visit specimens (defined as 2-4 months after enrolment), 69 third visit 
specimens (5-7 months after enrolment), 27 fourth visit specimens (8-10 
months after enrolment) and 9 fifth visit specimens (11-13 months). HPV 
prevalence was found to be: 67.26% (150/223) at baseline, 65.09% (69/106) 
at second visit, 60.87% (42/69) at third visit, 59.26% (16/27) at fourth visit 
and 66.67% (6/9) at fifth visit.  HPV prevalence is high in this population 
compared to other studies performed in HIV negative populations of similar 
age.  
 
Analysis of HPV variants isolated from South Africa couples 
The objective of the second study was to determine the concordance of 
infection with HPV 16, 58 and 53 variants within heterosexual couples. A total 
of 12 HPV 16 positive couples, eight HPV 58 positive couples and 12 HPV 53 
positive couples were identified from a cohort of South African heterosexually 
active couples. Specimens from these couples underwent HPV type-specific 
LCR PCR and sequencing to identify the variant present. In the 12 couples 
positive for HPV 16, ten were concordant (i.e. shared the same HPV 16 
variant), and two were discordant. For the eight HPV 58 positive couples; 
seven couples shared the same variant while partners in one couple had 
different variants. From the 12 HPV 53 couples; ten couples were concordant 
and two couples were discordant.  The majority of couples with HPV 
genotype-specific concordant infections shared the same variant of the 
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Human papillomavirus (HPV) is considered the most common sexually 
transmitted infection (STI) (Castellsague, 2008; Kjaer et al., 2001) and is 
causally associated with cervical cancer (Walboomers et al., 1999) as well as 
other cancers such as those of  the anus, oropharynx, penis, vagina and 
vulva (reviewed by Chaturvedi, 2010).  It is estimated that 75% of sexually 
active men and women will become HPV infected in their life time (Palefsky, 
2007; Da Ros and Schmitt, 2008). In this literature review, HPV molecular 
biology, prevalence of HPV in young women as well as HPV variants 
transmission between partners in a couple will be reviewed. 
 
1.1 Global burden of cervical cancer 
In 2008 cervical cancer was responsible for about 275 000 deaths 
worldwide and 85.5% of these deaths were from developing countries 
(Globocan, 2008). Compared to women from other world regions, African 
women have the highest cervical cancer incidence (Figure 1.1) (Globocan, 
2008). This is because women in Africa are most likely not to be screened 
Figure 1.1 Worldwide age standardized incidence (in grey) and mortality (in orange) rates of 













for cervical cancer and have treatment for pre-cancerous lesions (de 
Sanjose et al., 2007; Kitchener et al., 2006). Significant reductions have 
been achieved in both the incidence and mortality from cervical cancer in 
countries with well organised screening programs (Szostek et al., 2008). 
 
1.1.1 Cervical cancer in South Africa 
Recent data on the prevalence of cervical cancer are limited for South 
African women (Denny, 2010). Cancer registry data from 1993-1995 showed 
that an average of 3387 new cases of cervical cancer were reported annually 
in that time point (Sitas et al., 1998). In 1998 and 1999, a total of 6061 and 
5203 cases of cervical cancer were reported, respectively (Mqoqi et al., 
2004). Fonn and co-workers (2002) determined the age specific prevalence 
rates of cervical cancer in 20603 South African women from across the nine 
provinces. A total of 92 (0.45%) women, with an average age of 51.3 years, 
were found to have invasive cancer (Fonn et al., 2002). Currently, there are 
about 16.84 million females (≥ 15 years) at risk for cervical cancer in South 
Africa (WHO/ICO, 2010). Every year, the estimated number of new cervical 
cancer cases diagnosed in South Africa is 5 743, with 3 027 deaths due to 
cervical cancer (WHO/ICO, 2010).  
 
1.2 Other cancers caused by HPV 
HPV is also potentially associated with several other cancers besides 
cervical cancer. Based on molecular and epidemiologic evidence, it is well 
known that a fairly large proportion of cancers of the oropharynx, vagina, 
vulva, anus and penus are etiologically related to HPV infection (Chaturvedi, 
2010). Globally, HPV is associated with 100% cervical cancer cases, 90-93% 
of anal cancer cases, 40-64% vaginal cancer cases, 12-63% of 
oropharyngeal cancer cases, 40-51% cancer cases of the vulva and 36-40% 














Table 1.1 Burden of HPV related cancers (Chaturvedi, 2010). 
 Cervix Anus Oropharynx Penis Vagina Vulva 
Molecular and 
Epidemiological 
evidence for a 
causal association 
with HPV 
+ + + + + + 
Proportion of 
cancers attributable 
to HPV infection (%) 





70-76 93 89-95 63-87 80-88 80-86 
Annual number of 







Annual number of 




1152-6048 NA 16000-25600 
 
Annual number of 








(NA)= not applicable 
 
1.3 Cofactors associated with progression to cervical cancer 
High risk (HR) HPV infection is a necessary but not sufficient cause of 
cervical cancer; therefore, other cofactors are necessary for progression of 
HR-HPV infection to cervical cancer (Figure. 1.2) (Moscicki et al., 2006).  
Figure 1.2 Factors associated with the natural history of HPV and progression to invasive 












Hence, the most crucial steps in cervical carcinogenesis are not only the 
acquisition of an HPV infection, but also the steps involving progression from 
a normal cervix to precancerous lesions (Moscicki et al., 2006).  
 
Cervical lesions caused by HPV infection differ in severity and are 
cytologically classified as atypical squamous of undetermined significance 
(ASCUS), low-grade squamous intraepithelial lesions (LSIL) and high-grade 
squamous intraethelial lesions (HSIL). The LSIL is the early stage of cervical 
disease and is classified histologically as cervical intraepithelial neoplasia 1 
(CIN1). The HSIL is the advanced stage of cervical disease and is classified 
histologically as cervical intraepithelial neoplasia 2/3 (Wright et al., 2007). 
 
Smoking, high parity, HPV type, multiple HPV types, Chlamydia trachomatis 
(CT), micronutrient depletion, and long term use of oral contraceptives (OC) 
have been suggested to be important determinants in the initial stage of 
severe cervical lesions (Castellsague and Munoz, 2003; Deluca et al., 2011; 
Gargiulo et al., 2007; Gariglio et al., 2009; Matos et al., 2005; Pista et al., 
2011; Wang et al., 2009; Xi et al., 2002).  The above cofactors are thought to 
act by influencing the acquisition of HPV infection, increasing the risk of HPV 
persistence and lastly by increasing the risk of progression from HPV 
infection to cervical lesion eventually leading to cancer of the cervix 
(Castellsague and Munoz, 2003).  
 
1.3.1 Environmental factors 
 Contraceptive use 
It has been suggested that long term use of oral contraceptive (OC) is 
associated with the development of cervical cancer in HPV infected 
individuals (Castellsague and Munoz, 2003; Moscicki et al., 2006). Not all 
studies have confirmed this, Shapiro et al (2003) reported that neither 
combined oestrogen/progestogen OC nor injectable progestogen increased 
the risk of clinically evident invasive cervical cancer (ICC) in South African 












been thought to be due to sexual activity rather than a direct effect from OC 
(Xi et al., 2002). However a recent study investigated the direct effect of OC 
use and found that oral contraceptive users are 85% less likely to clear HR-
HPV infections than non-users (Marks et al., 2011). Oestrogen/progesterone 
is known to increase the risk of cancer by suppressing the immune system 
(Marks et al., 2011). 
 
Other studies infer that long term oral contraceptive use does not influence 
the acquisition or the persistence of HPV infection but rather enhances the 
probability of malignant transformation of the infection (Bertram, 2004; 
Vaccarella et al., 2006). A possible mechanism for this phenomenon is that, 
hormonal contraceptives may increase the expression of viral oncogenes by 
interacting with the estrogen responsive elements (ERE) on the long control 
region (LCR) (Chen et al., 1996a). Together the LCR with E2 are responsible 
for HPV transcriptional regulation.  Therefore a positive interaction between 
estrogen and ERE on the LCR may result in the viral genes expression, 
replication and transformation (Lopez-Saavedra et al., 2009). 
 Parity 
High parity is associated with viral persistence and increased risk of cervical 
cancer (Castellsague and Munoz, 2003; Louie et al., 2009a; Moscicki et al., 
2006). Whereas nullparous women have a lower risk of squamous cell 
carcinoma of the cervix compared to parous women (Munoz et al., 2002). 
The risk of developing squamous cell carcinoma of the cervix further 
increases among parous women with increasing number of pregnancies 
(Munoz et al., 2002). An explanation for the increased risk of cervical 
carcinoma among women who are multiparous because their transformation 
zone is maintained on the exocervix and result in direct exposure to HPV and 
other cofactors (Autier et al., 1996; Liao et al., 2012; Munoz et al., 2002).  
 Smoking as a risk factor for cervical cancer 
Smoking is one of the cofactors contributing to the progression of HPV 












Schmeink et al., 2011). Cigarette contain carcinogens such as 
Benzo[a]pyrene, which upregulate the amplification of HPV genome which in 
turn may increase the chances of viral integration into the host genome 
causing progression to cancer of the cervix (Alam et al., 2008).  In an 
analysis of HR-HPV persistence and associated risk factors in a cohort 
composed of young unscreened women, the number of lifetime sexual 
partners and smoking were associated with HR-HPV type persistence 
(Schmeink et al., 2011). Smokers were found to have a two-fold increased 
risk of HR-HPV persistence (Schmeink et al., 2011). Together cofactors such 
as multiple infections, multiple sexual lifetime partners and smoking were 
found to increase the risk of HR-HPV persistency (Schmeink et al., 2011). 
HPV 16 positive women who are current smokers are particularly at higher 
risk of progressing to HSIL (Wang et al., 2009). Current smokers were found 
to have a significantly increased risk of developing squamous cell cervical 
carcinoma compared to non-smokers (Appleby et al., 2006). This risk 
increased in relation to the number of cigarettes smoked per day and with 
decreased age at starting smoking. Furthermore past smokers had a lower 
risk of squamous cell carcinoma than current smokers (Appleby et al., 2006). 
Collins and colleagues (2010) reported that current young women who 
smoke and who are sexually active are twice as likely to be diagnosed with 
high grade lesion compared to non-smokers (Collins et al., 2010). However, 
other studies have found no difference in persistence between current 
smoker and current non-smokers (Maucort-Boulch et al., 2010). 
 
Castellsague and Munoz (2003) concluded that smoking; long term OC use 
and parity are co-factors that regulate the risk of progression from HPV 
infection to HSIL and eventually to cervical cancer. Therefore, multiparous 
women that are current smokers and use OC need closer monitoring for HPV 
infection and cytological abnormalities then women in the general population 














 Infections with other microorganisms and increased risk of cervical 
cancer 
HPV is more common in HIV infected women than in HIV negative women 
(Denny et al., 2012), particularly in those women who are 
immunocompromised with low CD4 lymphocytes (Jamieson et al., 2002; 
Strickler et al., 2005). Memiah and others (2012) found a positive correlation 
between precancerous cervical lesions and CD4 count. Women with CD4 
<200/ul were found to be 1.6 time more likely to develop precancerous 
cervical lesions (Memiah et al., 2012). In a recent South African study 
investigating HPV incidence and clearance in both HIV positive and negative 
men and women followed at six months intervals for a period of 24 months,  
a higher detection rate of new HPV in HIV positive men and women was 
reported compared to HIV negative men and women. HIV positive men and 
women had a significantly lower rate of HPV clearance compared to HIV 
negative men and women (Mbulawa et al., 2012). Among HIV positive 
women from Cape Town younger than 60 years of age, it was found that HIV 
positive women with ICC were on average 6 years younger than HIV 
negative women (Moodley et al., 2006). Another study investigating HIV 
prevalence among women with cervical cancer, mean age was 41 years from 
KwaZulu Natal, reported that HIV infected women were on average 13 years 
younger than HIV negative women (Moodley et al., 2005). 
 
Chlamydia trachomatis (CT) is another well-known microorganism to play a 
major role in the aetiology of CIN by facilitating the infection and persistence 
of HR-HPV (Deluca et al., 2011). Association between CT and HPV is not 
unusual, since they share the same route of sexual transmission (Oh et al., 
2009; Simonetti et al., 2009).  Deluca and others (2011) demonstrated a 
significant association between concurrent CT and HPV infection. Oh and co-
workers (2009) found a positive association with the number of lifetime 
sexual partners, husband’s extramarital sexual relationships, and cytological 
abnormalities to be significant for HR-HPV types, but not for CT.  According 
to Simonetti et al (2009) the possible association between CT and HPV 












inflammatory mediators, causing a change in  cell to cell adhesion, and 
affecting cell differentiation (Simonetti et al., 2009). Madeleine and others 
(2007) speculated that the inflammatory response and metaplasia triggered 
by CT infections promotes cell cycle and therefore increases the number of 
non-dividing differentiating cells that are needed for HPV replication 
(Madeleine et al., 2007). 
 
Herpes simplex virus type 2 (HSV-2) is another well-known microorganism to 
contribute to progression to CIN. It has been suggested that HSV-2 infections 
acting together with HPV infection may increase the risk of ICC (Smith et al., 
2002). This is due to the fact that HSV-2 also infects cervical squamous 
epithelial tissues found in the squamous-columnar junction, the site where 
invasive cervical cancer arises (Smith et al., 2002). 
 
1.4 HPV structure and genome organisation 
HPVs are small non-enveloped double stranded (ds) DNA viruses almost 
55nm diameter in size. They have a circular genome composed of 
approximately 8000 base pairs (bp) in size which is wrapped inside a protein 
shell (Munoz et al., 2006). The genome consists of three regions namely; the 
early (E) coding region, late (L) coding region and the long control region 








Figure 1.3 Schematic representation of the HPV 16 genome, presenting early region in 
green and red (E1, E2, E4 and E5 as well as the oncogenes E6 and E7). The late region 












The LCR, which is also known as the upstream regulatory region (URR), 
contains the origin of replication and the P97 early promoter, but does not 
code for proteins (Donne et al., 2010; Veress et al., 2001; Vinokurova and 
von Knebel, 2011). The HPV genome encodes six early proteins termed (E1, 
E2, E4, E5, E6 and E7) and two late proteins which are L1 and L2 (Figure 
1.3), which are essential for the replication of the viral DNA and the assembly 
of newly synthesed virus particles (Doorbar, 2006; Munoz et al., 2006).  The 
E1 gene encodes a protein necessary for viral genomic replication (Wilson et 
al., 2002). The E2 gene product plays a role in both the transcription and the 
replication of HPV. Protein encoded by the E2 gene has a regulatory effect 
on the transcription of the transforming proteins E6/E7 (Schmidt et al., 2005). 
The E1 and E2 proteins are also involved in maintaining viral latency by 
minimizing the expression of viral proteins in order to evade the host cellular 
immune surveillance (Pittayakhajonwut and Angeletti, 2010; Schmidt et al., 
2005; Wilson et al., 2002). E4 protein is present in large concentration during 
late HPV infection and is involved in the release of particles (Doorbar et al., 
1986). E4 is also required to form a complex with E1 for the efficient 
execution of productive phase of HPV 18 (Wilson et al., 2007). The E5 plays 
a role in transformation, a study done by Maufort and others (2010) showed 
that the E5 protein, in conjunction with prolonged estrogen treatment, 
induced cervical cancer in E5 transgenic mice (Maufort et al., 2010). E6 and 
E7 proteins are expressed at low levels during the infectious process and are 
the primary oncoproteins (de Sanjose et al., 2010; Frazer et al., 2011; 
Schiffman et al., 2007). HPV oncogenes E6 and E7 encode proteins that 
interact with tumour suppressor proteins and deregulate the cell cycle’s 
control mechanisms by creating genomic instability (Doorbar, 2006; 
Mazumder et al., 2011). Malignant progression of cervical neoplasia is 
associated with the expression of these oncoproteins (de Sanjose et al., 
2010; Schiffman et al., 2007). E6 blocks apoptosis by inhibiting p53 and E7 
inhibits retinoblastoma protein (pRB) which halts cell cycle arrest.  The L1 
and L2 genes encode structural proteins making up the viral capsid which are 
produced late in the infectious cycle of HPV and enclose the circular double 












Table 1.2 Papillomavirus encoded proteins: site in infected keratinocytes and function  
Protein 
name 
Site in infected keratinocytes Protein function 
E1 Nucleus, basal cells Necessary for viral genomic replication 
E2 Nucleus, basal cells Necessary for viral genomic replication  and 
has regulatory effect on the transcription of 
the transforming proteins E6/E7 
E4 Cytoplasm, spinous layer Involved in the release of viral particles 
E5 Transmembrane, spinous layer Plays a role in transformation 
E6 Nucleus, basal, spinous Required to maintain S-phase-like state during 
cell cycle, blocks apoptosis by inhibiting p53 
E7 Nucleus, basal, spinous Required to maintain S-phase-like state, 
inhibits retinoblastoma protein (pRB) which 
halts cell cycle arrest 
L1 Nucleus, mature squames Major capsid protein 




























1.5 HPV classification 
The family Papillomaviridae contains 29 genera which are composed of 
189 papillomavirus types (Figure 1.4) (Bernard et al., 2010).  
Figure 1.4 Phylogenetic tree of Papillomavirus types based on alignment of the L1 open 














Of the 189 papillomavirus types; 120 types are from humans, 64 types are 
from non-human mammals, 3 types from birds and 2 types are from 
reptiles (Bernard et al., 2010). Of the 120 HPV types that have been 
characterized there are about 40 types which have been found in the 
genital tract (Bernard et al., 2010; Jung et al., 2004; Munoz et al., 2006).  
 
HPV genotypes differ by 10% in DNA sequences based on the L1 open 
reading frame (ORF) (Bernard et al., 2010; de Villiers et al., 2004). Types 
that are closely related, by approximately 80-90%, are classified as 
members of the same species. They usually share important biological 
properties, such as tissue tropism and pathogenicity (Bernard et al., 2010; 
Chow et al., 2010). Subtypes are defined as being different by 2-10% from 
any HPV types (de Villiers et al., 2004). HPV variants differ by less than 
2% in the L1 gene and by up to 5% in the LCR (de Villiers et al., 2004; Ho 
et al., 1993a). 
 
HPVs can be divided into two groups (Doorbar et al., 2012), according to 
the site of infection, these are the mucosotropic group (Castellsague, 2008; 
Chow et al 2010) and the cutaneotrophic group (Castellsague, 2008; 
Chouhy et al., 2010).  The mucosotropic group is found in the Alpha 
genera, which is the largest genus (Figure. 1.4) composed of 15 species 
which infects the upper aerodigestive tract, head and neck mucosa and the 
anogenital tract (Chow et al., 2010).  This genus can be further subdivided 
into three categories depending on the frequency with which they cause 
cervical cancer, as either; high risk (HR), probably high risk and low risk 
(LR) (Table 1.3) (Doorbar, 2006; Chow et al., 2010; Jung et al., 2004).  
 
Table 1.3 Classification of HPV types according to the frequency associated with cervical 
cancer (Bernard et al., 2010; Dobec et al., 2009; Munoz et al., 2003).  
Risk associated with 
cervical cancer 
HPV types 
Low risk 6 ,11, 40, 42, 54, 55, 61, 62, 64, 67, 69, 70, 71, 72, 81, 83, 
84, 89,  and IS39 
Probably high risk 26, 53 and 66 












Of the HR-HPV types, HPV 16 is associated with 53.5% of cervical cancer 
cases worldwide; while HPV 18 is associated with 17.2% cases (Figure 
1.5) (Castellsague, 2008; Clifford et al., 2006). Together HPVs 16, 18, 45 
and 31 are responsible for 80.3% cases of global cervical cancer (Bosch et 

















Figure 1.5 HPV types associated with cervical cancer (Clifford et al., 2006, adapted from 
Munoz et al., 2004). 
 
1.6 Association of HPV types, multiple infections and viral load with 
abnormal cervical cytology 
HPV factors involved in the progression of an HPV infected cervix to invasive 
cancer include HPV type, single or multiple infections and viral load 
(Castellsague and Munoz, 2003; Moscicki et al., 2006). It is known that the 
clearance rate of HR-HPVs is lower than for low risk (LR) HPV types, since 
HR-HPV types tend to have a higher viral load (Trottier et al., 2008). HR-HPV 
types with high viral loads are associated with HSIL (Hesselink et al., 2009). 
Kovacic and others (2006) investigated the associations of cytologic 
abnormality with viral load of type-specific HPV infection. An increased viral 
load of any single HR-HPV type was associated with cytologic abnormalities 












(consisting of HPVs; 16, 31, 33, 35, 52, 58 and 67) and α11 (consisting of 
HPVs 34 and 73) (P trend<0.0001), especially HPV 16 (P trend<0.0001). The 
association between abnormal cytology and viral load was also significant for 
α5/α6 types (P trend<0.04) and slightly significant for α7 type (P trend<0.05). 
There were no significant association for noncarcinogenic HPV types from 
α1/α8/α10/α13 (P trend<0.5) and α3/α15 species (P trend<0.4). It was found 
that the percentage of cytologic abnormality varied greatly depending on the 
infecting carcinogenic HPV species with respect to its viral load (Kovacic et 
al., 2006). This further suggests that carcinogenic high viral load in ≥ cervical 
intraepithelial neoplasia 2 (CIN2) is not only uniquely associated with HPV 16 
infection (Gravitt et al., 2007). The association between ≥ CIN2 and HR-HPV 
types with high viral load was significant even after excluding women with 
HPV 16 (Kovacic et al., 2006).  
 
Table 1.4 Percentage of women with atypical squamous cell of undetermined significance 
(ASCUS) or worse cytologies by qualitative viral load (Kovacic et al., 2006).  
PCR signal strength was expressed as; 1 indicating a low viral load, 2-3 indicates an 
intermediate viral load and 4-5 indicate the highest viral load.  
 
HPV 16 is the most frequent HPV type in cervical cancer irrespective of 
geographical area (Trottier et al., 2008), and is the type most likely to be 
associated with progression to CIN3 (Schiffman et al., 2009; Winer et al., 
2005). Since HPV 16 has a higher intratypic variation than other HR-HPVs 
(Schiffman et al., 2010; Raiol et al., 2009), it has been suggested that this 
type is not as efficiently cleared by the immune system as other HR types 












a correlation between HPV 16 viral load and rapid progression from infection 
to CIN3 (Dalstein et al., 2003; Santos et al., 2003; Xi et al., 2011). 
 
Several studies have concluded that women with multiple HPV infections are 
at higher risk for developing HSIL compared to women infected by single 
HPV type (Mejlhede et al., 2009; Pista et al., 2011; Spinillo et al., 2009; 
Trottier et al., 2008). Other studies have found no association between 
multiple HPV infections with developing HSIL (Bosch and Munoz, 2002; 
Selva et al., 2009). This is due to the fact that in individuals infected with 
multiple HPV types, HSIL is caused by a single HPV type. It is speculated 
that other types are likely to be minor and have no additional risk contributing 
to neoplasia (Gargiulo et al., 2007). Therefore if the multiple infections are 
due to noncarcinogenic HPV types, then this will not increase the risk of 
developing cervical cancer even though noncarcinogenic HPV types may 
have a high viral load (Gravitt et al., 2007; Kovacic et al., 2006). 
 
1.7 HPV variants 
HPV genotypes differ by more than 10% from each other in DNA sequence 
based on the L1 open reading frame. HPV types that are closely related by 
approximately 80-90% are classified as members of the same species 
(Bernard et al., 2010). HPV variants differ by less than 2% in the L1 gene 
and by up to 5% in the LCR (Calleja-Macias et al., 2005; de Villiers et al., 
2004; Ho et al., 1993a). Therefore, the LCR is the most variable region in 
the entire HPV genome (Chan et al., 2011; Ho et al., 1993a). 
 
The LCR contains regulatory elements that are involved in viral DNA 
replication and transcription of various factors that either suppress or activate 
the p79 promoter (Cornet et al., 2012; Lei et al., 2011; Pande et al., 2008). 
The p79 promoter is located upstream of the oncogenic early genes (Cripe et 
al., 1990) and is responsible for the regulation of various HPV genes, 
including the E6 and E7 oncogenes (Lei et al., 2011; Pande et al., 2008). The 












2012; Mazumder et al., 2011). Therefore sequence variations in the LCR and 
E6/E7 oncoproteins may reflect different oncogenetic potential among 
different HR-HPV variants (Kammer et al., 2002; Veress et al., 1999). 
Furthermore, an assessment of HPV variants with the severity of lesion 
should be determined in order to determine the risk of different HPV variant 
in cervical carcinogesis (Cento et al., 2011; Chan et al., 2002; Chang et al., 
2011; Pande et al., 2008). 
 
The LCR is divided into three functionally distinct regions which are termed; 
5’ region, central region and 3’ region (Figure 1.6). The 5’ region is 
approximately 300 base pairs (bp) in size, and is located between the L1 stop 
codon and the E2 binding site (O’Connor et al., 1995). This region contains 
nuclear matrix attachment regions and signals for transcriptional termination 
(Stunkel and Bernard, 1999). The central region is located between two E2 
binding sites namely E21 and E22 (Figure 1.6), and is approximately 400 bp 
and contains epithelial cell-specific enhancer (O’Connor et al., 1995; Stunkel 
and Bernard, 1999). The 3’ region is 140 bp and contains the origin of 
replication (ori) (Kammer et al., 2000; O’Connor et al., 1995; Stunkel and 
Bernard, 1999). 
Figure 1.6 Organization of HPV 16 LCR. The LCR is divided into three main regions termed; 














Studies have shown that variants of specific HPV types are often grouped 
according to the specific geographic area or human ethnic group from which 
they were isolated (Burk et al., 2009; Ho et al., 1993b; Lizano et al., 2009; 
Ong et al., 1993; Tanzi et al., 2009). HPV 16 variants are grouped into five 
distinct phylogenetic branches based on the LCR sequences (Figure 1.7) (Ho 















Figure 1.7 HPV 16 phylogenetic tree based on LCR sequences (Tanzi et al., 2009) 
 
These separate branches were found to correspond to specific ethnic groups 
or geographic locations; Asian (As), Asian American (AA), African 1 (Af1), 
African 2 (Af2) and European (E) (Ho et al., 1993b; Tanzi et al., 2009). The 
inclusion of the E6 gene, gives greater phylogenetic resolution resulting in 
the addition of an additional branch termed the North American variant (NA) 












grouped the E branch with the As branch to form the European-Asian (EAS) 
branch and grouped the NA branch with AA branch to form the Asian-
American/ North-American (AA/NA) branch. Therefore variants of HPV 16 
are currently grouped into four major branches based on E6 and LCR which 
are; European-Asian (EAS), African 1 (Afr1), African 2 (Afr2) and North 
American/Asian American (NA/AA) (Cornet et al., 2012). 
 
There are two major variants in Africa termed African 1 and African 2 
variants. Both the African 1 and African 2 lineages consist of sublineages 
namely; Afri1a, Afr1b, Afr2a and Afr2b. The Afr1a sublineage is found mostly 
in sub-Saharan Africa while the Afr1b lineage is found mostly in North Africa. 
The Afr2a sublineage is almost evenly distributed between sub-Saharan and 
North Africa while Afr2b is more prevalent in Sub-Saharan Africa than North 
Africa. The As sublineage is prevalent in Eastern Asia and the Eur 
sublineage is distributed across the globe. The NA sublineage is found 
frequently in North Africa while the Asian American 1 (AA1) and Asian 
American 2 (AA2) sublineages of the AA branch are both commonly found in 
South/Central America, with the AA1 sublineage most prominent in Asia 
(Cornet et al., 2012). Although the distribution of variants show 
ethnogeographic predilection some variants do exist in other regions; 
however not with the same prevalence as in their original geographic location 
(Tu et al., 2006). 
 
There is limited knowledge of HPV 58 sequence variation (Canche et al., 
2010; Chan et al., 2011; Raiol et al., 2009). The phylogenetic tree of HPV 58 
based on the LCR nucleotide sequences suggests that variants of this type 
have evolved into 4 lineages, termed A, B, C and D (Figure 1.8) (Chan et al., 
2011; Chen et al., 2011a; Liu et al., 2012). The ethnogeographic separation 
of HPV 58 lineages is not as conspicuous as that for HPV 16 variants. 
Nonetheless the distribution of HPV 58 variants does show some association 
with ethnogeographic origin (Chan et al., 2011). Lineage A is the most 
prevalent lineage, occurring worldwide. It can be divided into three 












Lineage B is more common in America than Africa and is subdivided into 
sublineages B1 and B2. Lineages C and D are more prevalent in Africa than 
America and Europe. Lineage C has not been subdivided into sublineages, 
while lineage D can be subdivided into sublineages D1 and D2 (Chan et al., 
2011; Godinez et al., 2013). 
Figure 1.8 Phylogenetic tree of HPV 58 LCR sequences showing four lineages: A, B, C and 
D. Black and white arrows show the two most prevalent variant sequences (Chan et al., 
2011) 
 
HPV 53 variants do not reveal any ethnogeographic clustering (Oliveira et al., 
2012; Wyant et al., 2011), but instead split into two lineages consisting of 
prototype-like (P-L) and non prototype-like (non P-L) variants (Cento et al., 
2012; Kocjan et al., 2007; Oliveira et al., 2012; Prado et al., 2005; Wyant et 
al., 2011). Based on the LCR both lineages further form star-like phylogenetic 












oncogenic potential of variants belonging to a particular cluster (Kocjan et al., 
2007; Wyant et al., 2011). Alterations within the LCR may affect the binding 
affinity of cellular and viral transcriptional factors (Wyant et al., 2011), such 
as Yin Yan 1 (YY1) factors (Park et al., 1999). However further studies are 
needed to clarify such assumption (Kocjan et al., 2007). 
 
Figure 1.9 Phylogenetic tree of HPV 53 with two distinct braches (Kocjan et al., 2007). 
 
1.7.1 HPV variants and associations with cervical diseases  
All HPV 16 variants are carcinogenic (Schiffman et al., 2010) but some 
variants may have higher oncogenic potential compared to others (Bokal et 
al., 2010; Hildesheim et al., 2001; Lizano et al., 2006; Schiffman et al., 2010; 
Sichero et al., 2012). These differences in carcinogenicity may likely be 
explained by differences in the biological, chemical and pathogenic 
properties of the variants, as well as difference in the host’s immunological 
response. Sequence variation may affect viral gene expression and viral 













The difference in carcinogenicity of HPV 16 variants may be due to mutation 
at the various transcriptional factor binding sites. The LCR contains 
transcription factor binding sites for the activation of transcription of the HPV 
oncogenes, E6 and E7. Mutations occurring in this region could therefore 
interfere with the activities of transcription factors and may potentially have 
significant role in tumorigenesis (Stephen et al., 2000). For example, YY1 
factors are known to play a role in the maintenance of low levels of HPV 
transcription (Park et al., 1999) by repressing the p79 promoter (Stephen et 
al., 2000). YY1 also inhibits the LCR activity responsible for the expression of 
the E6/E7 oncogenes (Park et al., 1999; Stephen et al., 2000). Therefore 
mutations of YY1 motif in the LCR could lead to increase levels of HPV gene 
expression (Park et al., 1999), resulting in viral persistence and cell growth 
changes (Lace et al., 2009; Park et al., 1999).  
 
Hildesheim and others (2001) investigated the risk of developing cervical 
cancer in HPV 16 positive women infected with specific HPV 16 variants. 
Results showed that the prevalence of non-European variants was 15.3% in 
high grade squamous intraepithelial lesions (HSIL) and 43.7% of cervical 
cancer. For European like variants, results showed that the prevalence was 
10.7% in HSIL and 0% cancers. These results provide evidence that different 
HPV 16 variants differ in oncogenicity (Hildesheim et al., 2001). Non-Eur 
variants are reported to have an increased oncogenic potential compared to 
Eur variants (Berumen et al., 2001; Hildesheim et al., 2001; Kammer et al., 
2000; Lei et al., 2011; Ordonez et al., 2004; Pista et al., 2007; Sichero et al., 
2007; Tornesello et al., 2004). Among Portuguese women non-Eur variants 
showed a significant statistical difference in frequency from 7.3% in normal 
cytology to 59.3% in invasive cervical cancer. African variants were 
associated with significant increased risk and were found in 44.4% cases of 
invasive cervical cancer (Pista et al., 2007). Among Italian women, non-Eur 
AA variant was found increasing with severity of lesion from 5.9% in CIN1 to 
19.4% in ICC (Tornesello et al., 2004). However among Slovenian women, 












non-Eur variants were only found in 5% cases (Bokal, et al., 2010). Similar 
finding were observed in a South African study, European variants were 
responsible for 79% of ICC, 14% were associated with African variants and 
only 7% were associated with AA variants (Tu et al., 2006). Therefore the 
increase virulence observed with non-Eur variants in various populations may 
not be caused by inherent differences in virulence of different HPV 16 
variants but reveal the ability of a given population to effectively mount a 
rigorous immunologic response against a specific HPV 16 variant prevalent 
(Tu et al., 2006). 
 
In a recent study that attempted to identify sequence variation of HPV 58 that 
could possibly carry a higher oncogenic risk, isolates carrying mutations 
G63S and T20I in the E7 gene were reported to have an independent risk for 
CIN3 and invasive cervical cancer. These high risk signature mutations were 
found in 33% of isolates from Asia, 10% in America, 3% in Europe but not 
found in Africa (Chan et al., 2012).  
 
HPV 53 variants may have different oncogenic potential however there is 
little knowledge regarding HPV 53 variants (Oliveira et al., 2012; Wyant et al., 
2011), further studies are need to confirm such speculations  (Kocjan et al., 
2007). 
 
Mutations in LCR of HPV contribute to the alternative mechanism involved 
in the oncogenicity of HPV and demonstrate a correlation between HPV 
infection and progression to cervical cancer (Chan et al., 2012; Pientong et 
al., 2013). Therefore since HPV variants differ by up to 5% in the LCR 
(Calleja-Macias et al., 2005; de Villiers et al., 2004; Ho et al., 1993a), it 
renders LCR the best appropriate surrogate for understanding oncogenetic 
potential of different HPV variants. This is due to the fact that the LCR 
contains regulatory elements that are involved in viral DNA replication and 
transcription of various factors that either suppress or activate the p79 












p79 promoter is located upstream of the oncogenic early genes (Cripe et 
al., 1990) and is responsible for the regulation of various HPV genes, 
including the E6 and E7 oncogenes (Lei et al., 2011; Pande et al., 2008). 
The E6/E7 oncogenes are involved in the formation of tumours (Mazumder 
et al., 2011). 
 
Due to the above reasons, we therefore focused on studies that have 
investigated various regions of the LCR, since this region has been 
deemed the most appropriate surrogate for understanding HPV variants 
oncogenicity. Results from various studies investigating HPV 16, 58 and 53 
LCRs are summarised below in Table 1.5. Please note that the South 
African Study done by Tu et al (2006) is not included in the table below due 












Table 1.5 Review of studies describing HPV 16, 58 and 53 variants based on LCR  
HPV 16 variants 









India Pande et al., 
2008 
E6, E7, L1 
and LCR 





LCR variants consisted of 38 Eur, eight AA, seven Afr1, two Afr2 
and five new variants. A total of 17 nucleotide substitutions were 
observed in the region (7521-13), the most common nucleotide 
substitution was a transition G7521A. 
India Bhattacharjee  









LCR variant analysis revealed that 55 isolated belonged to the Eur 
lineage and 6 isolates belonged to the AA lineage 
Mexico Lugo-Trampe 
et al., 2012 










LCR variant analysis showed that 176 isolates cluster with the Eur 
lineage, 53 isolates were from the AA lineage and 11 isolates 
clustered with the Afr2 lineage. A total of 31 nucleotide substitutions 
were observed in the region (7433-83), the most common nucleotide 













The most common HPV 16 lineages found in cervical isolates 
among Slovenian women in descending order were; Eur lineages 
(95%), Afr (2.5%) lineages and the (2.5%) AA lineages. A total of 44 
nucleotide substitutions were observed in the region (7161-7947), 
the most common nucleotide substitution was a transition G7519A. 
 
Poland Schmidt et al., 
2001 








Cervical cancer isolates mostly contain changes in sequences of 
YY1 binding sites whereas isolates from asymptomatic carriers 
harbour nucleotide changes within or close to transcription binding 
sites. Cervical cancers isolates mostly carried the transition mutation 
G7519A. 
Italy Tanzi et al., 
2009 







A total of 14 different HPV 16 LCR variants were found, consisting of 
ten Eur lineages, two Asiatic lineages and two Afr2 lineages. A total 
of 26 nucleotide substitutions were observed in the region (7315-31), 






















Finland Kurvinen et 
al., 2000 





A total of 14 HPV 16 LCR variants were observed, consisting of 13 
Eur lineages and one As lineage. Eur variants did not show 
enhanced pathogenicity. A total of 26 nucleotide substitutions were 
observed in the region (7139-145), the most common nucleotide 
substitutions were a transversion G7193T and a transition G7521A. 
Uganda Buonaguro et 
al., 2000 
E6, E7, L1 
and LCR 













HPV 16 Afr1 variant was identified in 100% tumours, 6.25% cervical 
scrapes and was associated with cancer progression. A total of 20 
nucleotide substitutions were observed in the region (7419-84), the 
most common nucleotide substitutions were the transitions G7419A, 
G7488A, T7763C, and T7785C. 
 
Zambia Lei et al., 
2011 






A total of 11 HPV 16 positive isolates were analysed, consisting of 
five Eur wild-type and six novel HPV 16 variants. From the six novel 
HPV 16 variants, five were identified as Eur variants and the 
remaining variant fell into the Afr lineage. A total of 12 nucleotide 
substitutions and six insertions were observed in the region (7405-
83), the most common nucleotide substitutions was a transitions 
G7797A.  
Thailand Chansaenroj 










All specimens harbouring single HPV 16 infections had Eur variants 
whereas all HPV 16 multiple infected specimens had non-Eur 
variants. Furthermore single HPV 16 infections caused by the Eur 
variant may significantly increase the risk for developing cervical 
cancer whereas multiple HPV 16 infection caused by non-Eur 
variants may require many variations to enhance the risk of cervical 
cancer development. A total of 23 nucleotide substitutions were 
observed in the region (7175-7886), the most common nucleotide 


































HPV 16 variants may be useful for investigation the risk of cervical 
neoplasia and could be informative for the design of HPV 16 vaccine 
strategies. A total of 26 nucleotide substitutions were observed in 
the region (7485-7842), the most common nucleotide substitution 
was a transition G7521A. 









HPV 16 non-Eur variants were frequently observed in 
adenocarcinomas. A total of 32 nucleotide substitutions were 
observed in the region (7450-7876), the most common nucleotide 
substitution was a transition G7489A. 
China Shang et al., 
2011  
E6, E7, L1 
LCR  





The most prevalent HPV 16 variants were from the Eur lineage 
(67.13%) followed by the As lineage (32.69%). A total of 32 
nucleotide substitutions were observed in the region (7168-48), the 
most common nucleotide substitution was a transition G7521A. 
Italy Tornesello et 
al., 2004 
E6, E7, L1 
and LCR 





Non-Eur variants were found to be more oncogenic compared to Eur 
variants. A total of 17 nucleotide substitutions were observed in the 
region (7432-83), the most common nucleotide substitution was a 
transition G7521A. 









HPV 16 A A variants were found to be more oncogenic compared to 
Eur variants. A total of 14 nucleotide substitutions were observed in 
the region (7585-83), the most common nucleotide substitution was 
a transition G7521A. 
Uganda Tornesello et 
al., 2000 





Rearrangements within the HPV 16 LCR were found in two out of 
five penile carcinomas suggesting that natural variants may play a 
significant role in the pathogenesis of genital carcinoma. A total of 
seven nucleotide substitutions were observed in the region (7289-
93), the most common nucleotide substitutions were the transitions 
the G7489A and   G7521A. 
Uganda Tornesello et 
al., 1997 
E6, E7, L1 
and LCR 







HPV 16 Afr1 variant were found integrated in four out of five penile 
carcinoma isolates.A total of 20 nucleotide substitutions were 
observed in the region (7420-83), the most common nucleotide 
substitution was a transition G7519A. 









HPV 16 Afr variants were associated with increased risk for cervical 
cancer. A total of 13 nucleotide substitutions were observed in the 































HPV 16 LCR phylogeny revealed 69% of variants were from the Eur 
lineage, 19% were from the A A lineage and 12% belonged to the As 
lineage. A total of 13 nucleotide substitutions were observed in the 
region (7485-7842), the most common nucleotide substitution was a 
transition G7521A. 








HPV 16 phylogenies did not show correlation between ethnicity and 
HPV 16 variant in a Brazialn population consisting of mixed races  
A total of 16 nucleotide substitutions were observed in the region 
(7485-7839), the most common nucleotide substitution was a 
transition G7521A. 









Mutations in the LCR may alter the oncogenicity of HPV in the 
following two ways, either by changing amino acid sequences of the 
oncoprotiens E6 and E7 or through alterations to transcriptional 
binding sites. A total of 25 nucleotide substitutions were observed in 
the region (7521-24), the most common nucleotide substitution was 
a transition A7767G and G7769A. 
Korea Park et al., 
1999 






Nucleotide substations at the YY1 binding site are associated to the 
development of cervical neoplasia. A total of 18 nucleotide 
substitutions were observed in the region (7484-24), the most 
common nucleotide substitution was a transition G7520A. 
Brazil  Alencar et al., 
2007 





A total of 12 Eur, Eight AA, one Afr1 and one Afr2 HPV 16 LCR 
variants were characterised. A total of 29 nucleotide substitutions 
were observed in the region (7233-7886), the most common 




Watts et al., 
2002 
E2, E4, E6 
and LCR 





A majority (82%) of the variants belonged to the Eur lineage, 12% 
belonged to the As branch and 2% belonged to the AA lineage. A 
total of 41 nucleotide substitutions were observed in the region 
(7172-73), the most common nucleotide substitutions were a 
transversionG7193T & a transition G7521A. 
Colombia Moreno-












HPV 16 phylogeny showed that a (88.2%), of variants belonged to 
the Eur lineage 8.8% of samples had AA lineages and in 2.9% of 
samples the HPV 16 lineage could not be identified. A total of nine 
nucleotide substitutions were observed in the region (7436-7786, the 





















Canada Mayrand et 
al., 2000 







A total of 46 (92%) of women had persitant infection. A total of 28 
nucleotide substitutions were observed in the region (7172-7495), 
the most common nucleotide substitution was a transversion 
G7192T. 












Eight clones belonged to the Eur lineage and the remaining two 
clones were identical to the Afr2 lineage based on the LCR only, but 
showed similarities with the Eur lineage in the E6 region, therefore 
were termed recombinations.  A total of nine nucleotide substitutions 
were observed in the region (7764-90), the most common nucleotide 
substitution was a transversion A90T. 









HPV 16 variants can be separated into nine sublineages as 
following; Eur, As, Afr1a, Afr1b, Afr2a, Afr2b, NA, AA1, and AA2, 
base on the E6/LCR. A total of 27 nucleotide substitutions were 
observed in the region (7175-83), the most common nucleotide 














Overall, a total of 313 (4.0%) of nucleotide positions were found to 
vary in the entire HPV 16 genome. A total of 49 nucleotide 
substitutions were observed in the region (7175-83), the most 
common nucleotide substitutions were a transversion G7193T & a 
transition G7521A. 
Singapore Ho et al., 
1993a 








HPV 16 variant concordance was observed in Four out of eight 
couples. A total of 13 nucleotide substitutions were observed in the 
region (7483-7840), the most common mutation was at position 
7519 (nucleotide substitution was not shown). 










LCR variant analysis revealed that 14 isolates were from the Eur 
lineage, 35 isolates from the As lineage and two isolated were from 
the AA lineage. Mutations in the Y Y1 motifs in the LCR increase the 
expression of viral oncogens. 
Mexico Kammer et 
al., 2000 






The E6-proximal end of the LCR is responsible for the enhanced 
transcriptional activities of the AA and NA variants. A total of 53 mutations 
were observed in the region (7060-83), the most common were; G7060T, 
































The different oncogenic potential seen in HPV 16 Eur variants may 
be due to alterations of E6 proteins instead of altered activity of the 
P97 promoter. A total of 32 nucleotide substitutions were observed 
in the region (7033-78), the most common nucleotide substitution 
was a transversion G7193T and transitions G7521A. 









LCR variant analysis revealed that 61% of isolates clustered with the 
As lineage, 8.5% clustered with AA lineage, 25.6% clustered with 
the Eur lineage, 3.7% clustered with the Afr2 lineage and the 
remaining 1.2% was termed J135C. A total of  38 nucleotide 
substitutions were observed in the region (7193-81), the most 
common nucleotide substitutions were  transversions; A7175C, 
G7193T, A7287C , A7730C, G81T transitions T7177C, T7201C, 
G7521A, C24T  & transition/tranversion  G7842A/T 
Paraguay Mendoza et 
al., 2013 





Eur variants were detected among women with and without normal 
cytology while non-Eur variants were detected only in women with 
cervical lesions.A total of 15 nucleotide substitutions were observed 
in the region (7485-7834), the most common nucleotide substitution 




























HPV 58 variants 
























HPV 58 variants can be grouped into four lineages revealing 
some degree of predilection in distribution. A total of 24 
nucleotide substitutions were observed in the region (7257-
7429 and 7540-52), the most common nucleotide substitution 
was a transversion C30G. 










There was no correlation between HPV 58 variant and 
abnormal cervical cytology. A total of 30 nucleotide substitutions 
were observed in the region (7118-7540), the most common 
nucleotide substitution was a transition C7266T. 












The most prevalent lineage was the A3 lineage 56.52% 
followed by A2 (26.09%), A1 (15.65%) and C (1.74%). A total of  
20 nucleotide substitutions were observed in the region (7421-
7775), the most common nucleotide substitution was a 
transversions/transition A7714C/G 









Phylogenetic analysis of HPV 58 isolates did not show ethnic 
clustering. A total of 12 nucleotide substitutions were observed 
in the region (7265-7788), the most common nucleotide 
substitution was a transition T7575C. 









Twelve variants were identified and eight of the variants 
belonged to the prototype-like group. The remaining four 
variants belonged to the non prototype-like group.  
A total of nine nucleotide substitution were observed in the 
region (7714-86), the most common nucleotide substitution was 
transition/transversion A7793G/C 













Based on the LCR, a total of 149 isolates belonged to the A 
lineage and 24 isolates could not be classified. Only one isolate 
belonged to the B lineage. 
 A total of 21 nucleotide substitutions were observed in the 
region (7257-7421 & 7540-52), the most common nucleotide 














HPV 53 variants 


















HPV 53 phylogeny revealed two lineages which further 
formed star-like clusters. A total of 29 nucleotide 
substitutions were observed in this region (7380-14) 
consisting of 27 single nucleotide exchanges, one 1 bp (T) 
and one 4 bp (TGGG) insertions. The most common 
nucleotide change was the transition G7508A 









 HPV 53 phylogenetic analysis did not reveal any 
ethnogeographical clustering. A total of 21 nucleotide 
substitutions were observed in the region (7422-7810). The 
most common nucleotide change was the transition G7508A 











No specific association was found between nucleotide 
substitutions and grade of cytological lesions.A total of 17 
nucleotide substitutions  were observed in the region (7422- 














1.8 HPV life cycle 
HPVs infect the basal cells of stratified epithelium of mucosal and cutaneous 
skin (McBride, 2008; Pittayakhajonwut and Angeletti, 2010). In a normal 
epithelium, only cells in the lower basal layers are dividing mitotically and 
after cell division, one daughter cell is pushed up to restore the overlying 
differentiated layers. These cells are eventually sloughed from the surface of 
the epithelium (McBride, 2008). However during HPV infection, the outcome 
of the infection depends on several factors which include the site of infection, 
HPV type, host’s immune system and differentiation of the host cell (Burchell 
et al., 2006; Doorbar, 2005; Doorbar, 2006; Schlecht et al., 2003). The latter 
factor is due to the fact that HPV genome replication is determined by the 
host’s mitotically active cells (Cheng et al., 1995; Culp et al., 2006; Kadaja et 
al., 2009; McBride, 2008). 
 
There are two stages in which HPV replicates and amplifies its genome, and 
these are termed, non-productive and productive cycle (Pittayakhajonwut and 
Angeletti, 2010). In the non-productive stage, infection is initiated when the 
virus enters the epithelium through microabrasion and reaches the 
undifferentiated dividing basal cell layers (Figure 1.10) (Cheng et al., 1995; 
Leggatt and Frazer, 2007; McBride, 2008; Moody et al., 2010; Munoz et al., 
2006; Pittayakhajonwut and Angeletti, 2010; Pyeon et al., 2009). The virus 
enters the basal epithelial cells and reaches the host cell’s nucleus where it 
replicates and remains as a viral episome (McBride, 2008), and no progeny 
virus produced. Viral DNA replication is achieved with the assistance of the 
early genes, E1 and E2 which induce the host’s cellular DNA synthesis in 
order for the virus to utilize cellular replication proteins under S phase control 
(de Sanjose et al., 2010; Frazer et al., 2011; Narisawa-Saito and Kiyono, 
2007; Pittayakhajonwut and Angeletti, 2010; Schiffman et al., 2007). E6 and 
E7 proteins are required to maintain S-phase-like state so that cellular 
replication machinery is available (McBride, 2008). As the basal cells divide 
through mitosis they differentiate to produce identical copies of themselves 
containing viral genes as episomes (Cheng et al., 1995; Evander et al., 1997; 












Figure 1.10 Biology of maturing squamous epithelium altered by an HPV infection (Leggatt 
and Frazer, 2007 reproduced from Munoz et al., 2006). The left side show expression sites 
of HPV non-structural proteins (E1, E2, E4, E6 and E7) and structural proteins (L1 and L2) 
as well as structural alterations to the epithelium caused by HPV infection. The right side of 
the Figure shows a normal maturing squamous epithelium. 
 
The second stage of HPV amplification and replication is termed the 
productive cycle (Pittayakhajonwut and Angeletti, 2010).  In the productive 
cycle the HPV DNA copy number is increased to hundreds or thousands per 
cell resulting in the production of progeny genomes which are ready to be 
encapsulated into virion particles (McBride, 2008). The process of viral 
genome amplification, late capsid protein synthesis and virion assembly 
occur in the upper, terminally differentiated cells of the epithelium (McBride, 
2008; Pittayakhajonwut and Angeletti, 2010). Virions are assembled in the 
superficial differentiated layers and are found throughout the nuclei (McBride, 
2008). The E4 gene assists in the expression of late genes in the squamous 
layer (Leggatt and Frazer, 2007; Munoz et al., 2006; Wilson et al., 2007).  
The late genes L1 and L2 make up the viral capsid which now encapsulates 
the HPV genome in the mature squamous layer (Florin et al., 2002; Leggatt 
and Frazer; Munoz et al., 2006). The process of viral encapsulation involves 
the expression of the minor coat protein L2 and L1 major coat protein 
(Doorbar et al., 2012). The cells containing viruses are now destined to be 












2009; Leggatt and Frazer, 2007; McBride, 2008; Moody et al., 2010; 
Narisawa-Saito and Kiyono, 2007).  
 
1.8.1 Progression to cervical cancer  
HPV infections result in the establishment of the viral genome as a stable 
episome in the basal layer cells characterized as low grade squamous 
intraepithelial lesions (LSIL) (Figure 1.11). In such lesions, the expression of 
gene products is carefully maintained in low levels with viral proteins 
produced at regulated levels at specific times as the infected cells move 
towards the epithelial surface (Doorbar, 2006; Kadaja et al., 2009; Moody et 
al., 2010). 
Figure 1.11 Changes in expression patterns that follow progression to cervical cancer 
(Doorbar, 2006). The pattern of viral gene expression changes during cancer progression. 
During LSIL (CIN1), the sequence of events is similar to that observed in productive lesions 
(diagrammatically on the far left). Whereas in HSIL, the start of late events is delayed, and 
although the order of events remains the same, the production of infectious virions becomes 
limited to smaller areas close to the epithelial surface. Integration of HPV sequences into the 
host cell genome can accur at the same time with these changes and may result to further 
deregulation in the expression of E7 and the loss of E1 and E2 replication protein.  In 
cervical cancer (shown diagrammatically of the far right), the stages of the HPV life cycle are 
no longer sustained and viral episomes are normally lost. 
 
Normally in low-grade lesions, HPV DNA exists as a double stranded circular 
episome (Huang et al., 2008). However in a majority of cervical cancer cells, 
a significant proportion of the HPV genome is integrated (Huang et al., 2008; 












linearises and integrates itself with the host’s genome in the cell nucleus. 
Linearization of HPV genome results in disruption of the E2 gene open 
reading frame (Huang et al., 2008; Palefsky, 2006). The disruption of the E2 
gene results in the loss of ability to down regulate the expression of the 
transforming proteins E6/E7 (Palefsky, 2006; Schmidt et al., 2005). This 
leads to the inactivation of tumor suppressor gene products caused by E6 
and E7 (Doorbar, 2006; zur Hausen, 2002; von Knebel et al., 1991). E6 
blocks apoptosis by inhibiting p53 and E7 inhibits retinoblastoma protein 
(pRB), which normally stops cell cycle progression in keratinocytes. This 
results into uncontrolled cell division. Abnormal cells expressing large 
quantities of E6 and E7 multiply from the basal epithelial layers to the mature 
squamous layer (Munoz et al., 2006; zur Hausen, 2002; Schiffman et al., 
2007). Elevated expression of the oncogenes protein E6/E7 contribute to 
cancer progression and the levels of E6 and E7 increase from LSIL to 
cervical cancer (Figure 1.11) (Doorbar, 2006). 
 
1.9 Natural history of HPV infection 
Cervical cancer usually develops after a long period of latency (Arnouk et al., 
2009). The development occurs via a series of steps, namely, HPV infection, 
viral persistence, and progression of persistently infected cell to pre-cancer 
and eventually to cervical cancer (Figure 1.12) (Schiffman et al., 2007).  
Figure 1.12 Stages leading to the development of cervical cancer after HPV infection 












HPV prevalence peak is observed in women less than 25 years of age 
(Cuschieri et al., 2004; de Sanjose et al., 2007). This is followed by a decline 
in DNA detection in the age group beyond 30 years (de Sanjose et al., 2007). 
The incidence of pre-cancers rise progressively for women over 25 years and 
cancer incidence are highest for women over 40 years (Bosch et al., 2008; 
Khan et al., 2005; Schiffman and Kjaer, 2003; Snijders et al., 2006).  
 
Anogenital HPVs are normally transmitted through sexual contact with an 
infected individual (Kjaer et al., 2001). The virus enters the cells of the 
epithelium through microabrasion in the skin and reaches the basal layers 
(Munoz et al., 2006). HPV infections of the cervical epithelium are associated 
with expression of non-structural viral proteins which induce minor alterations 
to epithelial cells causing squamous intraepithelial lesions (SIL) (Frazer et al., 
2011). In the majority of individuals HPV infections are cleared and the 
clearance period of most HPV infections is approximately 6-12 months 
(Schmeink et al., 2013). However, in a minority of individuals whose immunity 
fails to clear the infection, the HPV infection will progress to cause 
precancerous lesions which is the next step towards advancing to cervical 
cancer (Doorbar, 2006). Around about 40% of untreated HSIL cases 
progress to invasive cancer (Castellsague et al., 2008; Peto et al, 2004). The 
period taken by HPV from initial infection to progress and cause HSIL takes 
about a decade (Ault, 2006; Plummer et al., 2007; Schiffman et al., 2007).   
 
HPV 16 and 18 are the most persistent HR-HPV types, and together with 
other cofactors, such as; viral, environmental and host factors, can cause 
lesion that will eventually develop to cancer (section 1.3). The duration from 
HPV infection to cervical cancer normally takes between 10-20 years 
(Moscicki et al., 2006; Schiffman and Castle, 2005). Hence cervical cancer is 
very rare in women under 25 years, the incidence rises progressively for 
women over 25 years and is highest for women over 40 years (Khan et al., 













In a study done by Matsumoto et al (2011), women with CIN1/2 were 
followed up at 3 to 4 month intervals, in order to evaluate the risk of disease 
progression associated with HPV genotypes. Findings showed that the 
cumulative probability CIN1/2 for progressing to CIN3 within 5 years for HPV 
16, 18, 31, 33, 35, 52 and 58 was 20.5% while the probability for other HR 
types was 6% and 1.7% for LR types (Matsumoto et al., 2011). Sandri and 
co-workers (2009) evaluated the prevalence and association of HR-HPV 
genotypes with cervical lesions of different severity in 199 women. Results 
showed an increase in the prevalence of HPV 16 infection from 21.3% in 
CIN1 to 71.9% in CIN3 (Sandri et al., 2009). Among women that were 
surgically treated, genotype specific persistence was evaluated in order to 
predict the development of residual or recurrent disease during follow-up. 
Results revealed that HPV 16 was the most common HPV type associated 
with recurrent disease, with a frequency of 55.6%. The prevalence of HPV 16 
increased with severity of cervical disease, from a prevalence of 23.1% in 
CIN1 to 45.5% in CIN2 and eventually to 75.6% in CIN3 (Venturoli et al., 
2008). 
 
HPV 18 is the second most frequent HPV type in ICC (Guan et al., 2012), 
and is responsible for a fifth of cancer cases (Schiffman et al., 2011). HPV 18 
was found to have an absolute risk of future CIN2+ of 25.6% (Naucler et al., 
2007). However it has been reported that studies using CIN3 as the principal 
outcome end point for cervical cancer underestimate the carcinogenic 
potential of HPV18 compared to other HR types (Bulk et al., 2007; Guan et 
al., 2012). This is because HPV 18 varies very little between normal cytology 
and CIN3 but has been found to increase significantly in ICC (Guan et al., 
2012). 
 
From these studies it is clear that the risk of persistence and progression 
varies among HR-HPV types to cause cervical cancer (Matsumoto et al., 
2011). Hence it is useful to test for type-specific HPV in women with LSIL in 
order to identify women who are at increased risk of disease progression 












al., 2006). HPV typing is able to distinguish between HPV positive women 
with HR-HPV from those women with LR-HPV. Furthermore women who are 
positive for HPV 16 and / or HPV18 may be subjected to an intensive follow 
up since they have an elevated risk of CIN3+ as oppose to HR-HPV positive 
women who test negative for those two types (Meijer et al., 2006).  
 
1.10 Age-specific prevalence of HPV and geographic variation of HPV 
prevalence in young women 
Genital HPV infection is highly prevalent in young women that are sexually 
active (Ho et al., 1998; Iftner et al., 2010; Smith et al 2008). Overall HPV 
prevalence varies by age and country (Smith et al., 2008). However in most 
regions of the world HPV prevalence infection increases from 14 years 
through 25 years then decrease with increasing age thereafter (de Sanjose et 
al., 2007; Dunne et al., 2007; Kjaer et al., 2008; Smith et al 2008). There is a 
notable difference in HPV prevalence in middle aged women between the 
ages 35 to 50 years. In middle aged women, HPV prevalence was found 
highest (20%) in African women and Central/ South American women 
compared to women from Asia/Australia, Southern Europe/Middle East and 
Northern Europe with approximately 15% HPV prevalence (Smith et al., 
2008). 
 
In a worldwide meta-analysis study in which the age and genotype specific 
prevalence of cervical HPV was estimated in 157 879 women with normal 
cytology reported that approximately 10.4% women have HPV infection at 
any given point in time (de Sanjose et al., 2007). Overall distribution of HPV 
types in descending order was; HPV 16 (2.5%), HPV18 (0.9%), HPV 31 
(0.7%), HPV 58 (0.6%) and HPV 52 (0.6%). HPV prevalence was highest 
(15.5%) in women from less developed countries compared to 10.0% in 


































Figure 1.13 World estimates of age-specific HPV prevalence according to development 
status of specific country (de Sanjose et al., 2007). 
 
 A distinct geographic pattern which showed a second peak in women over 
the age of 44 years was observed in women from Africa, Northern America, 
Central and South America and Europe but not seen in Asian women (Figure 
1.14) (de Sanjose et al., 2007).  
Figure 1.14 HPV prevalence stratified according age among women from various world 




The highest prevalence of HPV was for African women with 22.1% when 
compared with women from other world regions (de Sanjose et al., 2007). A 
recent meta-analysis study of cervical HPV prevalence in 1 016 719 women 












HPV prevalence in descending order was as following; HPV 16 (3.2%), HPV 
18 (1.4%), HPV 52 (0.9%), HPV 31 (0.8%) and HPV 58 (0.7%). HPV 
prevalence was slightly higher (11.8%) in women from less developed 
countries compared to 11.3% in women from more developed countries. HPV 
prevalence was highest in all regions in women younger than 25 years of age 
and declined thereafter at middle age. A second peak was observed at age 
40 years or older and was clearly conspicuous in women older than 55 years 
in Africa. A second peak was not clearly pronounced in women from the 
Asian continent (Bruni et al., 2010). 
 
In a South African study HPV prevalence was 20.4% (173/848) in women 
with normal cytology aged 21-59 years old. In descending order, the most 
frequently detected HR-HPV types were, HPV 16 (2.00%), HPV 52, (1.9%), 
HPV 45 (1.4%) and HPVs 18 and 68 (1.3%) (Allan et al., 2008). In another 
South African study of the prevalence of HR-HPV and distribution among HIV 
negative women aged 17-65 years with and without cervical intraepithelial 
neoplasia, 71.5% (902/1261) of women with normal cytology were HPV 
positive. HPVs 35, 16 and 58 were the three most frequently detected HR-
HPV types in women with normal cytology (McDonald et al., 2012).  
 
Since my M. Sc thesis investigated HPV prevalence in HIV negative women 
from Durban, South Africa aged 14-30 years, more detail is given reviewing 
HPV prevalence in the respective age bracket between 10 to 30 years of 
age. HPV prevalence trends among young women aged ≤30 years from 
various world regions are lowest among European women compared to 
North American and African women (Figure 1.15) (Castellsague et al., 2001; 
Healey et al., 2001; Iftner et al., 2010; Mbulawa et al., 2010; Silva et al., 
2011). In a European study done by Silva and others (2011) in Portugal 
characterizing HPV infection status in 277 female adolescents aged 14 to 30 
years old HPV was present in 46/277 (16.6%) women. The most common 
HPV types were HPV 31 (15.2%) followed by HPV 16 (13.0%) and finally 












Figure 1.15 HPV prevalence variations in young women aged 10-30 years from various 
world regions (Castellsague et al., 2001; Dobec et al., 2009; Healey et al., 2001; Iftner et al., 
2010; Mbulawa et al., 2010; Silva et al., 2011). 
 
Among German females aged 10-30 years, HPV prevalence was 22.28% 
(377/1692). Females in the age group 20-22 years were found to have the 
highest prevalence of 28.3% (Iftner et al., 2010). In Switzerland HPV 
prevalence was 26.26% (47/179) among women aged ≥30 years. The 
prevalence of HPV was highest 28% (39/139) among women aged 21-30 
years and prevalence of HR-HPV types was 15.1% (Dobec et al., 2009). The 
prevalence of HPV was determined among 2065 Dutch specimens obtained 
from women aged 18 to 29 years. Results showed that 393 (19%) women 
were HPV positive. The prevalence of HR-HPV types was 11.8% and 9.1% 
for LR types. The most prevalent HPV detected were HPV 16 (2.8%), HPV 
51 (2.5%), and HPV 52 (2.5%) (Lenselink et al., 2008). In Italy, the HPV 
status of 1006 women aged 18-24 years was determined and findings 












243 HPV positive women, 175 (72%) women had HR-HPV types. The most 
common HPV type was HPV 16 with a prevalence of 4.5% followed by HPV 
53 (2.7%), HPV 84 (2.6%), HPV 42 (2.5%), HPV 62 (2.4%) and lastly HPV 66 
and HPV 89 both with a prevalence of 2.2% respectively (Ammatuna et al., 
2008). Whereas among North American aboriginal women in Canada aged 
13-30 years the prevalence of HPV was 34.86% (251/720). In this Canadian 
study the prevalence of HPV was 42.08% (101/240) in women aged 13-20 
then declined to 31.25% (150/480) among women aged 21-30 years (Healey 
et al., 2001). 
 
In South America, HPV was determined in 206 virgins from Costa Rica aged 
18-26 years who were followed semi-annually for a median of 3.6 years after 
being sexually active. Results showed a cumulative HPV DNA detection of 
110/206 (53.4%) women testing positive for at least one infection at least 
once. Out of 110 HPV positive women, the identity of type specific HPV 
genotypes was possible in 105 women. The number of women which tested 
positive once for HR types were 79 (38.4%) while 80 (38.8%) tested positive 
once for LR types. HPV 16 was the most common HR types with a 
prevalence of 19 (9.2%) followed by HPV 66 with a prevalence of 16 (7.8%) 
and HPV 52 with a prevalence of 15 (7.3%). Among LR-HPV types, HPV 53 
was the most common with a prevalence of 19 (9.2%) (Rodriguez et al., 
2007). 
 
Among Asian women, the prevalence of HPV was determined in 1039 young 
Japanese women aged 20 to 25 years old at baseline. Their findings 
revealed that 355 (34.2%) women were HPV positive. HR-HPV types were 
detected in 304 (29.3%) and LR types were detect in 112 (10.8%). The most 
frequently detected HPV types was HPV 52 (8.1%) followed by HPV 16 
(6.5%), HPV 51 (4.5%), HPV 18 (4.0%) and HPV 31 (3.8%) (Konno et al., 
2011). 
 
The prevalence of HPV has been reported to be highest among African 












Mozambican and South African women aged ≤30 years respectively 
(Castellsague et al., 2001; Mbulawa et al., 2010), and may be influenced by 
HIV. High risk HPV prevalence was 55% in women aged 14-20 years and 
48% in women aged 21-30 years from Mozambique (Castellsague et al., 
2001). The overall prevalence of HR-HPV types in South African women 
aged ≤30 years was 62.30% (38/61). The most frequently detected HR-HPV 
types were HPV 53 (9.84%), HPV 35 (8.20%) and HPV 16, 18, 31 and 58 
(6.56%) and the most frequently detected LR-HPV were HPVs 61, 62 and 70 
(6.56%) (Mbulawa et al., 2010). In a recent African study done in a general 
population of Tanzanian women under the age of 25 (n=260) the prevalence 
of HR-HPV types was determined to be 24.6%. The most common HPV 
types were HPV 52 (6.5%), HPV 16 (5.4%), HPV 66 (4.2%), HPV 35 (3.8%) 
and HPV 56 (2.7%). Among 624 women in the age group of 25-29 years; the 
prevalence of HR-HPV types was 27.6%. The most common HPV types were 
HPV 52 (5.8%), HPV 51 (5.0%), HPV 16 (4.0%), HPV 35 (3.7%) and HPV 66 
(3.5%) (Dartell et al., 2012).  
 
In conclusion, results from the above studies indicate that genital HPV 
infections vary across different age groups in young women across 
geographical regions. This is due to differences in sexual behaviour, method 
used in selecting the study population and heterogeneity of HPV DNA 
detection techniques employed by various laboratories. 
 
1.11 HPV sharing in couples 
HPV is efficiently transmitted between sexual partners; consequently multiple 
transmissions within couples are also possible (Hernandez et al., 2008). HPV 
prevalence and concordance among couples depends on the couples’ sexual 
behaviour, sensitivity of test used and the differences between acquisition 
rates among women and men (Parada et al., 2010). Furthermore, the natural 
history of HPV infections between men and women varies because of the 
differences between the epithelium of the penis to that of the cervical 












HPV transmission occurs more frequently in sexually active couples in a 
monogamous relationship that use non-barrier forms of contraception 
compared to partners in transient relationships (Hernandez et al., 2008; 
Widdice et al., 2010). This may be due to the fact that partners in transient 
relationship have less time to transmit HPV infections (Widdice et al., 2010). 
The transmission rate of HPV is higher from female to male than male to 
female (Widdice et al., 2013).  
 
A recent study examined HPV concordance and transmission rates in 25 
heterosexual couples with a relationship of at least 3 months’ duration in 
which women were aged 13- 21 and the respective male partners were ≥18 
years from California. HPV DNA from genitals was sampled 5 times over a 6 
weeks period. Results of the study showed genital HPV concordance 
between the couples ranged from 64 to 95% for at least 1 HPV type. 
Transmission rates from the male genital to female genital ranged from 14.5-
100 per 100 person-months and for female genital to male genital ranged 
from 26.8- 187.5 per 100 person-months (Widdice et al., 2013). HPV 
transmission rates were found lower in a Hawaiian study in which HPV 
transmission was examined in 25 heterosexual monogamous couples 
followed up at 2 months in erval for an average period of 7.5 months. The 
mean age for men was 26 years and the mean age for women was 28 years. 
Finding showed that male to female transmission occurred in 7 couples and 
female to male transmission occurred in 12 couples. Infections transmitted 
from the male to the female all originated in the penis and the overall 
transmission rate was 4.9 per 100 person-month of exposure. By contrast 
infections transmission from the cervix and/ or urine to penis consisted of 
female to male events and the overall transmission rate was 17.4 per 100 
person-months of exposure (Hernandez et al., 2008). HPV transmission rates 
were lowest among Canadian couples in which women were aged 18-24 
years and their respective male partners were ≥ 18 years old. Transmission 
rates were report to be 3.5 per 100 person-months for male to female and 4.0 
per 100 person-months for female to male transmission. The duration of the 












(73/179), and which 83.6% (61/73) involved transmission of single HPV 
types. HPV transmission of 2 types was observed in 13.7 % (10/73) couples 
and 2.7% (2/73) involved the transmission of 3 types (Burchell et al., 2011). 
 
Among African couples, HPV concordance was found in 15.7% couples for 
any HPV types and 8.4% for high-risk HPV types among 166 Rwandan 
couples. The median age of the men was 31 years and the median age for 
women was 28 years (Veldhuijzen et al., 2012). HPV concordance was 
determined in 486 heterosexually active black South African couples with a 
mean age of 38 years for men and 35 years for women. A total of 10% of HIV 
negative couples had concordant HPV types while 48% of HIV positive 
couples shared HPV types. In HIV discordant couples i  which the male 
partner was HIV positive, 11% were HPV concordant while in HIV discordant 
couples where the female partner was HIV positive, 30% shared HPV types 
(Mbulawa et al., 2010). 
 
HPV prevalence and concordance among couples from the above studies 
vary and are influenced by many factors such as the couple’s sexual 
behaviour, HIV status and sensitivity of test employed. Investigating HPV 
transmission is mostly determined by genotyping for type specific 
concordance among partners in a couple. This approach is not precise and 
tends to overstate HPV transmission rate between couples. Therefore a 
better approach would be to investigate the transmission of HPV by 
identifying HPV variants through sequencing, which will enable the 
investigator to determine HPV transmission rates with a higher level of 
precision (Ho et al., 1993a; Lee et al., 2009). In the only study in which HPV 
transmission among respective partners in couples was determined by 
evaluating variant concordance, findings revealed that eight couples were 
HPV 16 positive; however HPV 16 variants were only shared in four out of 
eight couples. Partners in the other four couples had discordant HPV variants 














1.12 HPV vaccines 
Currently, there are two prophylactic HPV vaccines available; one was 
developed by Merck termed Gardasil and the other developed by 
GlaxoSmithKline termed Cervarix (Verheijen, 2011). These vaccines consist 
of virus like particles (VLP) derived from L1 major capsid proteins (Figure 
1.16) (Chen et al., 2000). The L1 major structural protein is used to produce 
vaccines (De la Rosa et al., 2009), since this protein has the ability to self-
assemble into VLPs in the absence of other papillomavirus proteins. The 
VLPs consists of 72 pentamers of L1 protein and are morphologically similar 
to native virions, but contain no DNA and (Chen et al., 2000). Although VLP 
are not infectious, they have the ability to induce neutralizing antibodies 
(Kirnbauer et al., 1992).  
 
Cervarix contains VLPs assembled from the L1 proteins of HPV 16 and HPV 
18 (Deschuyteneer et al., 2010). Gardasil also contains L1 VLPs from HPV 
16 and HPV 18 but in addition contains L1 VLPs derived from HPV 6 and 
HPV 11 (Donavan et al., 2011; Shank-Retzlaff et al., 2006). Together HPV 6 










Figure 1.16 HPV L1 virus like particle (VLP) structure (Stanley et al., 2006) 
 
Both vaccines are administered intramuscularly on three separate occasions, 
with Gardasil and Cervarix having 100% and 98% efficacy against cervical 
diseases caused by HPV 16 and 18, respectively (Table 1.6) (Botha, 2009). 
Cross protection against any lesions caused by non-vaccine oncogenic HPV 
types is 47.7% and 23.4% for Cervarix and Gardasil respectively (Brown et 












given to young children in the public health domain before sexual debut to 
decrease the burden associated with HPV (Moscicki, 2008), with Gardasil 
being the better option since it is the only registered vaccine for boys (CDC, 
2011; Georgousakis et al., 2012). The efficacy of Gardasil against HPV 16, 
18, 6 and 11 related external genital lesions in males aged 16-26 years was 
reported to be 79.0% among men who had sex with men and 92.4% among 
heterosexual men (Giuliano et al., 2011). 
 
Table 1.6 Commercially available vaccines (modified from Botha, 2009) 
Vaccine Gardasil Cervarix 
HPV types 6, 11, 16, 18 16, 18 
Dosing schedule 0, 2, 6 months 0, 1, 6 months 
Adjuvant AAHS (amorphous aluminium 
hydroxyphosphate sulphate) 
ASO4 (aluminium hydroxide 
+ MPL) 
VLP preparation system Yeast Insect cell 
Efficacy against disease 
caused by HPV types in the 
vaccine 
100% 98.1% 





In a recent study done by Draper et al (2011) in which the frequency and titre 
of neutralizing antibodies was determined against pseudoviruses 
representing genetically related HPV types from the Alpha (α) genera, 
species 7 consisted of five HPV types; 18, 39, 45, 59 and 68, and species 9 
consisted of six HPV types; 16, 31, 33, 35, 52 and 58. Determination of 
frequency and titre of neutralizing antibodies was done using sera from 
recently vaccinated young girls aged 13-14 years using the bivalent Cervarix 
vaccine. Results showed that, neutralizing antibodies against non-vaccine 
HPV types 31 and 33 from α9 were detected, while only neutralizing 
antibodies against non-vaccine HPV type 45 from α7 was detected (Draper 
et al., 2011).  
 
Wheeler et al (2009) evaluated the impact of a quadrivalent HPV vaccine on 
infection related to 10 non-vaccine HPV types; 31, 33, 35, 39, 45, 51, 52, 56, 
58 and 59. This was done to determine whether administration of the vaccine 
reduced the incidence of infection of ≥ 6 month’s duration. The rate of HPVs; 












The rate of HPV related CIN 1-3 was reduced by 18.8% and the rate of HPV 
types: 31, 58, 59 related CIN1 were reduced by 26%, 28.1% and 37% 
respectively (Wheeler et al., 2009). Therefore administration of quadrivalent 
HPV vaccine to partially infected individuals reduces the incidence of 
infection (Wheeler et al., 2009). 
 
The studies by Draper et al., 2011 and Wheeler et al., 2009 both 
demonstrated the vaccines’ ability to cross-protect against non-vaccine 
types, and may also be provided to women at risk for co-infection with both 
vaccine and non-vaccine HPV types (Draper et al., 2011; Wheeler et al., 
2009). In a head to head encounter, Einstein and co-workers (2009) 
compared the immune response elicited by both vaccines using the same 
methodology for assessment of immune response and reactogenicity. They 
found that HPV 16 and 18 neutralising antibody levels induced by Cervarix at 
month 7 were higher than those induced by Gardasil. Neutralizing antibodies 
levels against HPV 16 were 2.3-4.8 fold higher in the Cervarix group 
compared to the Gardasil group after the completion of the vaccination 
course. The level of HPV 18 neutralizing antibody induced by the two 
vaccines was found to be 6.8-9.1- folds higher in Cervarix when compared to 
Gardasil. Individuals vaccinated with Cervarix produced a higher positivity 
rate of cervicovaginal secretion neutralizing antibody against HPV16 and 
HPV 18 (Einstein et al., 2009). 
 
Epidemiological data on HPV prevalence and type distribution at baseline is 
crucial to evaluate the impact of HPV vaccines. Therefore, the data 
presented in this study serves as a starting point to aid in the understanding 
of the burden of HPV infection. Consequently, this information will be 
valuable for policy making regarding to HPV screening that would maximize 
the potential benefits of an HPV vaccine. Hence, we aim to establish cervical 
HPV type-specific prevalence, incidence and clearance rates in young rural 
and urban HIV negative woman who participated in an HIV prevalence trial 
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Viral prevalence is the result of acquisition of new infections (incidence) and 
duration (persistence) (Castle et al., 2005). HPV prevalence varies by 
country, regions within the country and population subgroups due to different 
sexual behaviour and screening methods used (Bruni et al., 2010; Clifford et 
al., 2005b; Dartell et al., 2012; De Vuyst et al., 2010; Dols et al., 2012; 
Menendez et al., 2010; Michala et al., 2012; Smith et al., 2008; Ting et al., 
2010; Thomas et al., 2004; Vinodhini et al., 2012).  
 
Data on HPV acquisition, clearance and persistence is needed in different 
populations to effectively design cervical cancer prevention strategies (Datta 
et al., 2012; Rositch et al., 2012). HPV acquisition is age dependant and is 
most common among young women (Castle et al., 2005; Liaw et al., 2001; 
Syrjannen et al., 2004; Thomas et al., 2000). Women younger than 35 years 
accumulate incident HPV infections more frequently than older women. The 
rate of acquisition is reported to be 3.7% per month in women younger than 
20 years (Syrjannen et al., 2004).  
 
Women 15-29 of age are more likely to clear HPV infections when compared 
to women older than 30 years of age (Safaeian et al., 2008). It is known that 
HPV infections clear within 6 months (Goodman et al., 2008), however it has 
been found that in majority of women, 80% of HPV infections are cleared 
within 18 mo ths (Oh et al., 2008). LR-HPV types clear more rapidly 
compared to HR-HPV types (Datta et al., 2012; Goodman et al., 2008). The 
rate of clearance among LR-HPV types is highest for HPV 11, HPV 61, HPV 
72 and HPV 84 (Datta et al., 2012). Among the HR-HPV types, HPV 16 is 
less likely to clear compared to other HR-HPV types (Bulkmans, et al., 2007).  
 
Clearance rates are lower for HR-HPV types and consequently persistence 
rates are higher for HR types compared to LR types (Datta et al., 2012; 
Rositch et al., 2012). It has been reported that HPV 16, 31, 33 and HPV 52 












A persistent HR-HPV type is necessary for the development of cervical 
cancer (Franco et al., 1999; Chen et al., 2011b). Although HPV persistence 
rate varies across different studies and is largely influenced by region of 
study and HPV type, analyzing the dynamics of HPV clearance against HPV 
persistence are useful in understanding the natural history of HPV. This will 
in turn aid to the prediction of whether a SIL will regress spontaneously or will 
persist and progress to cause HSIL and eventually cervical cancer (Datta et 
al., 2012; Fukuchi et al., 2009; Rositch et al., 2012). However an obstacle in 
determining such dynamics is that there are limited studies available for 
specific age groups (Rositch et al., 2012).  
 
2.2 The aims of the study 
(i) To investigate the prevalence of genital HPV infection in HIV-negative 
women aged 14-30 years in KwaZulu Natal 
(ii) To investigate HPV acquisition, clearance and persistence 
 (iii) To examined the prevalence of HPV and type distribution according to 























2.3 Materials and methods 
2.3.1 Study population 
Cervico-vaginal lavages were obtained from 434 HIV negative young women 
aged 14-30 years who were enrolled in the CAPRISA sero-incidence clinical-
trial preparedness study during 2005-2007. These participants were 
assessed for STI and received HIV testing in addition to HIV counseling on a 
three monthly basis for up to 13 months. There were 223 women at baseline, 
106 women at second visit (defined as 2-4 months after enrollment) and 69 
women at third visit (defined as 5-7 months after enrollment). There was an 
additional of 27 women at fourth visit (defined as 8-10 months after 
enrollment) and 9 women at fifth visit (defined as 11-13 months after 
enrollment). 
 
During enrollment these women also received cytological assessment of the 
cervix by conventional Papanicolaou (Pap) smear and results were provided 
to the respective participants during the study. Specimens were collected 
with voluntary informed consent and maintained in storage at -85°C. The 
University of KwaZulu Natal Biomedical Research Ethics committee reviewed 
and approved the protocol entitled ―HIV and STI incidence rates in Vulindlela: 
A prevention preparedness study. Q Abdool Karim, CAPRISA‖ (Ref: 
E197/03). This study was also approved by the Research Ethics Committee 
of the University of Cape Town (Ref: 459/2011).  
 
2.3.2 Preparation of cervico-vaginal lavages (CVL)  
A plastic bulb pipette was cut below the bulb and the tip was fastend to a 
10ml syringe then 5ml of phosphate buffered saline (PBS) was drawn. A 
warm water lubricated speculum was inserted into the vagina and the pipette 
was introduced through the speculum into the vagina. The pipette was 
directed towards the cervical os and squeezed to bath the cervix. The fluid 
was allowed to pool into the posterior fornix and aspirated into the same 












then dispensed into a sterile 30ml urine container. The CVL samples were 
stored on ice and transported on ice to the laboratory in less than 6 hours. 
The CVL specifmen were then aseptically transferred into a 15ml screw-
capped centrifuge tube. The specimens were centrifuged at 800g for 10 
minutes to fractionate the cellular component from the supernatant. The 
supernatant was aliquoted into cryovials and stored at -85°C. 
 
 
2.3.3 DNA extraction 
DNA from cervico-vaginal lavage (CVL) cell pellet was extracted for HPV 
typing using the Magna Pure Compact Nucleic Acid Isolation Kit I (Roche 
Diagnostics, Mannheim, Germany). This kit was used in conjunction with the 
MagNA Pure Compact Instrument (Roche Diagnostics, Mannheim, Germany) 
employing an automated extraction procedure performed according to the 
manufacturer’s instruction. The procedure utilizes; reagent cartridges, tip 
trays and elution tubes, which were all placed into their respective positions 
in the MagNA Pure Compact Instrument (Roche Diagnostics, Mannheim, 
Germany). Total volume of 400µl cervical samples in 2ml tubes were loaded 
onto the sample tube rack. Sealed reagents cartridges containing the 
following reagents; Proteinase K, lysis buffer, magnetic glass particles 
(MGPs), isopropanol, wash buffer I and II, and elution buffer were used. Lysis 
buffer containing guanidine salts was used to lyse the cells, Proteinase K and 
the salts were used to denature contaminating proteins, including nucleases. 
The DNA was immobilized onto the MGPs and then precipitated by the 
addition of isopropanol. The denatured protein and all other contaminants 
were then removed by washing with buffers containing absolute ethanol. 
DNA was released from the beads at 80°C and was eluted into a sterile 2ml 
tube in 200µl of elution buffer consisting of nuclease-free, sterilized water. 
The extracted DNA samples were then stored at -20°C until further use. DNA 
extraction was carried out in an area dedicated for nucleic acid extraction 
only, with the use of nuclease-free sterile tips and tubes. These 













2.3.4 PCR amplification and HPV genotyping 
The Roche Linear Array HPV Genotyping Test (Roche Diagnostics, 
Mannheim, Germany) was used for the detection of HPV types in specimens. 
This test was used because; it is very sensitive and specific. The test is 
suitable for high-throughput testing and can be used in large epidemiological 
studies. In addition the test has the ability to differentiate specific HPV types 
within the high and low risk groups, a feature which is not possible with the 
hybrid capture 2 test (Iftner and Villa, 2003). The hybrid capture 2 test is easy 
to perform in clinical settings and is suitable for automation. In addition it 
does not require special facilities to avoid cross-contamination since it does 
not rely on target amplification as compared the Roche Linear Array HPV 
Genotyping Assay to achieve high sensitivity. A limitation of the hybrid 
capture 2 test is that it only detects high risk HPV types (Iftner and Villa, 
2003). 
 
Preparation of specimens for PCR were carried out in a PCR-clean area, 
which is a room dedicated for making up PCR master-mixes. The 
precautionary measures were implemented to avoid contamination with 
amplified products. The amplification and detection of HPV types were done 
in a post-amplification area. DNA from clinical specimens was amplified using 
Roche Linear Array HPV genotyping and detection assay according to the 
manufacturer’s instructions (Roche Diagnostics, Mannheim, Germany). This 
assay utilizes the PGMY09/11 primers used to amplify the conserved L1 
region of 37 HPV genotypes in a single PCR. The reverse primers are biotin 
labelled at the 5’ end to allow the capture of alkaline denatured amplicons 
onto the streptavidin coated strips during post-amplification detection.  
 
HPV master mix contains the PGMY09/11 primers to amplify HPV DNA from 
37 types resulting in a 450 bp product and GH20/PC04 primers which were 
concurrently used to amplify 268 bp of the β-globin gene. The human β-
globin gene was co-amplified in the same PCR reaction to assess sample 












master mix also contains the enzymes AmpliTaq® Gold DNA polymerase 
and uracil-N-glycosylase (AmpErase); dNTPs including dUTPs. A Master Mix 
reagent in a total volume of 580µl was then mixed with 125µl of Magnesium 
chloride solution to give a working HPV master mix. The Mg2+ enhances the 
activity of AmpliTaq® Gold DNA polymerase. This enzyme extended the 
primers bound to target DNA for the amplification of HPV and human DNA. 
The AmpErase enzyme was used to eliminate carry-over contamination in 
PCR by catalyzing destruction of amplicons containing dUTP. This was done 
to ensure selective amplification of the required target DNA only. Fifty 
microlitres (µl) of DNA sample was added to 50µl aliquots of working HPV 
master mix and amplified in the amplification and detection area.  
 
Negative and positive controls from the kit were included in each 
amplification procedure. The negative control (50µl) has no HPV DNA while 
the positive control (50µl) has HPV 16 DNA. The post-amplification detection 
of 37 HPV types (HPV6, 11, 16, 18, 26, 31, 33, 35, 52, 58, 39, 40, 42, 45, 51, 
53-56, 59, 61, 62, 64, 66-73, 81-84, IS39 and CP6108) was done using the 
Linear Array Detection Kit (Roche Diagnostics, Mannheim, Germany). IS39 is 
a subtype of HPV 82 and CP6108 is also known as HPV 89 (Clifford et al., 
2005b).  
 
The following PCR conditions were performed on the GeneAmp PCR System 
9700 (Applied Biosytems) 96-well gold-plated machine at a ramp rate of 
50%: 50°C for 2 min to activate AmpErase, 95°C for 9 min, followed by 40 
cycles consisting of 95°C for 30 sec, 55°C for 1 min, 72°C for 1 min and a final 
hold at 72°C for 5 min. The reaction was kept at 72°C until the addition of an 
alkaline denaturation solution from Linear Array Detection Kit (Roche 
Diagnostics, Mannheim, Germany) to denature the amplicons and 
AmpErase. 
  
The denatured amplicon mixture (75µl) were then transferred to appropriate 












Linear Array HPV Genotyping strip which were included in the kit. The strip 
was coated with HPV and β-globin oligonucleotide probes immobilized onto 
membrane. Each amplicon hybridized to the strip at 53°C and was bound to 
the complementary probe with a matching sequence. There was one cross-
reactive oligonucleotide probe that hybridized with HPV 33, 35, 52 and 58. 
The Roche Linear Array HPV Genotyping test does not directly detect HPV 
52; instead it combines a set of probes detecting HPV 33, 35, 52 and 58 as a 
group. The specimens that test negative for HPV 33, 35 and 58 individually 
but test positive for the group will be deemed to be HPV 52 positive. 
Specimens that test positive for the group and for HPV 33 or 35 or 58 with 
uncertain HPV 52 status will be deemed HPV 52 negative, however HPV 52 
infection cannot be ruled out. Following hybridization and stringent washes 
with buffers containing SDS and sodium salts, streptavidin-horseradish 
peroxidase conjugate (SHPC) was added to the strip to bind to the biotin-
labeled amplicons hybridized to the probes on strip. A substrate mixture of 
hydrogen peroxide (H202) and 3,3’,5,5’-tetramethylbenzine (TMB) was added 
to each strip. The TMB substrate oxidised to a blue color by catalysis action 
of streptavidin-horseradish peroxidase in the presence of H202. The blue 
colour then precipitated at the probe positions and allow for the reading of 
strips.   
 
2.3.5 Statistical analysis 
X2 test (Epi Info version 5 Statcalc) was used in comparing prevalence 
between groups. P values ≤0.05 were considered significant. 
 
2.4 Results 
2.4.1 Description of the Roche Linear Array HPV Genotyping Test 
Each run included both the negative and positive control to ensure good 
quality of results. To ensure that there is no cross contamination between 
specimens in each run an empty well between specimens was left. Figure 












hybridization signals for HPV types as well as positive and negative control. 
The positive and negative controls were correctly determined therefore the 
run was successful. Samples; 172, 175, 183 and 186 were negative for HPV 
while samples 178 and 185 had only one type and specimens 174, 179, 180, 
and 184 have multiple HPV types. In this run we did not observe similar 
pattern of HPV types detected between specimens, therefore these findings 
indicate no evidence of cross contamination between specimens in a run. 
Figure 2.1B illustrates how the Linear Array HPV genotyping test reference 
guide was used to determine HPV types. In this sample both β-globin high 


















Figure 2.1A Roche linear array HPV genotyping strips demonstrating multiple HPV types 
without cross contamination. (A) Demonstrates results from 10 patients showing positive 
hybridization signals for HPV types as well as positive controls. Each run included both the 
negative (N) and positive (P) control to ensure that each run was successful.  Samples 172, 
175, 183 and 186 were all HPV negative while samples 178 and 185 had only one type and 
specimens 174, 179, 180, and 184 were all HPV positive with have multiple HPV types. (B) 
Roche linear array HPV genotyping strip demonstrating positive results with multiple HPV 


















2.4.2 HPV prevalence at baseline 
Overall baseline HPV prevalence in this cohort was 67.26% (150/223). The 
prevalence of single infections was 36% (54/150) while 64% (96/150) of 
specimens harbored multiple infections. Out of all infections observed, the 
prevalence of HR-HPV was 57.18% (219/383) and prevalence of LR-HPV 
was 42.82% (164/383). The most frequently detected HPV types were HPVs 
58, 62 (14.67%); HPV 61 (14.0%); HPV 51 (12.67%); HPVs 16, 52 (11.33%); 
HPV 53 (10.67%); HPV 68 (10.00%); HPVs 6, 39, 45 (9.33%). The least 
prevalent HPV types were; HPVs 11, 67, 69 (1.33%); HPVs 40, 82 (2.00%); 
HPVs 71, 89 (2.67%); HPV 26 (3.33%); HPVs 31, 56, 70 (4. 00%); HPV 42, 
IS39 (4.67%) and HPV 33 (5.33%) (Figure 2.2).  












From the 223 positively genotyped specimens, 46.64% (104/223) of 
specimens were from women aged 14-20 years and 53.36% (119/223) were 
from women aged 21-30 years. HPV prevalence according to age group was 
69.23% (72/104) in women aged 14-20 years and 65.55% (78/119) in women 
aged 21-30 years. 
 
2.4.3 HPV prevalence at second visit 
At the second visit defined as 2-4 months after enrollment, the prevalence of 
HPV was 65.09% (69/106). The prevalence of single HPV infections was 
27.54% (19/69) and the prevalence of multiple HPV infections was 72.46% 
(50/69). The prevalence of HR-HPV type was 62.87% (105/167) and LR-HPV 
prevalence was 37.13% (62/167). The most frequently detected HPV types 
were HPV 58 (21.74%); HPV 59 (15.94%); HPVs 16, 35 (14.49%); HPV 62 
(11.59%); HPVs 39, 51, 52, 54, 55 (10.14%); HPVs 18, 61, 70, 73 (8.70%) 
and HPVs 45, 53, 72, 83 (7.25%). The least frequently detected HPV types in 
ascending order were as following HPVs 11, 71 (1.45%); HPVs 6, 33, 42, 89, 
IS39 (2.90%); HPVs 26, 56 (4.35%) and HPVs 31, 66, 81, 84 (5.80%) (Figure 
2.3). 
 
2.4.4 HPV prevalence at third visit  
The HPV prevalence at third visit defined as 5-7 months after enrollmnt was 
60.87% (42/69). The prevalence of single HPV infections was 26.19% 
(11/42) and the prevalence of multiple HPV was 73.81% (31/42). HR-HPV 
prevalence was 55.12% (70/127) and prevalence of LR-HPV types was 
44.88% (57/127). The most frequently detected HPV types were HPVs 58, 61 
(19.05); HPV 51 (16.67%); HPVs 18, 35, 52, 54, 59, 62 (14.29); HPVs 6, 16, 
26, 45 (11.90%); HPVs 53, 56, 70, 89 (9.52%); HPVs 69, 71, 83, 84 and IS39 
(7.14%). The least frequently detected HPV types in ascending order were 
















Figure 2.3 HPV prevalence in HIV- negative young women at 2-4 months after first visit 
 
2.4.5 HPV prevalence at fourth visit 
There were very few (27 women) followed up to fourth visit defined as 8-10 
months after enrollment. HPV prevalence was 59.26% (16/27) and the 
prevalence of multiple HPV types was 68.75% (11/16) while that of single 
HPV types was 31.25% (5/16). HR-HPV prevalence was 62.79% (27/43) and 
the prevalence of LR-HPV types was 37.21% (16/43). The most commonly 
detected HPV types were HPV 18 (18.60%), HPV 62 (9.30%), and HPVs 51 














Figure 2.4 HPV prevalence in HIV- negative young women at 5-7 months after first visit 
 
2.4.6 HPV prevalence at fifth visit 
HPV prevalence was 66.67% (6/9) at fifth visit defined as 11-13 months after 
enrollment. The prevalence of both multiple and single HPV types was 50% 
(3/6). HR-HPV prevalence was 46.15% (6/13) and that of LR-HPV was 
53.85% (7/13). The most commonly detected HPV types were HPVs 53 and 
70 (15.38%). 
 
2.4.7 Prevalence of HPV stratified according to species 
When HPV types were grouped according to species, at baseline the overall 












(94/150), α9 HPV 55.33% (83/150), α7 HPV 48.67% (73/150), α5 HPV 24% 
(36/150), α6 HPV 22% (33/150), α10 18% (27/150), α13 HPV 8.00% 
(12/150), α11 7.33% (11/150), α1 HPV 4.67% (7/150), α14 HPV 2.67% 
(4/150) and α8 HPV 2.00% (3/150). Single infections in α3, α7 and α9 HPV 
species were observed in 11.70% (11/94), 10.96% (8/73) and 18.07% 
(15/83) respectively. The trends observed during follow up were increasingly 
significant for α7 HPV species (R2= 0.966) and α13 HPV species (R2= 0.967) 
(Table 2.1).  
 
Table 2.1 Prevalence of HPV species at different visits during follow-up 
 Baseline visit Second visit Third visit R2 Value 
α1 HPV species 4.67 2.9 4.76 0.002 
α3 HPV species 62.67 49.28 66.67 0.048 
α5 HPV species 24.00 17.39 42.86 0.509 
α6 HPV species 22 17.39 23.81 0.075 
α7 HPV species 48.67 50.72 54.76 0.966 
α8 HPV species 2.00 0.00 0.00 0.750 
α9 HPV species 55.33 69.57 64.29 0.387 
α10 HPV species 18.00 14.49 19.05 0.048 
α11 HPV species 7.33 8.70 4.76 0.413 
α13 HPV species 8.00 10.14 14.29 0.967 
α14 HPV species 2.67 1.45 7.14 0.557 
 
2.4.8 HPV incidence, persistence and clearance 
HPV acquisition was defined as the detection of a new HPV type that was not 
initially detected at previous visit. Acquisition of new HPV infection was 
46.23% (49/106) at second visit and of which 67.09% (53/79) were HR-HPV 
types and 32.91% (26/79) were LR-HPV types. The most frequently acquired 
HPV type was HPV 59 with a frequency of 10.13% (8/79) and the most 














Table 2.2 HPV incidence, persistence and clearance at different visits during follow-up 
 
When the prevalence of HPV acquisition was stratified according to HPV 
status, we noted that women who were HPV negative at baseline 27.03% 
(10/37) were less likely to acquire new HPV infections at second visit 
compared to women that were HPV positive at baseline 56.52% (39/69) (P = 
0.004). 
 
A total of 30.94% (69/223) women were followed up to third visit consisting of 
62.32% (43/69) women which were HPV positive at baseline and the 
remaining 37.68% (26/69) were women that were HPV negative at baseline. 
Acquisition of new HPV infections was 43.48% (30/69) at third visit. The 
prevalence of HR-HPV was 40.79% (32/63) while the prevalence of LR-HPV 
types increased from 32.91% (26/79) at second visit to 49.21% (31/63) at 
third visit (P=0.049) . The most frequently acquired HPV types were HPVs; 
18, 51, 52, 53, 54, 56, 59, 69 and 89 with a prevalence of 4.76% (3/63). The 
most frequently acquired HPV species was the α3 19.05% (12/63). 











































































































































 We also noted that women who were HPV negative at baseline 23.08% 
(6/26) compared to women that were HPV positive at baseline 58.13% 
(25/43) were less likely to acquire new HPV infections at third visit (P=0.005). 
It is possible that of the 25 women that acquired new HPV infections, 32.00% 
(8/25) had reactivation of HPV infection or acquired new HPV infections or 
their HPV type infection was below detectable levels at second visit. This is 
because the same HPV type(s) were detected at baseline visit and third visit 
but not at second visit. These HPV types were HPVs 6, 16, 18, 51, 53, 54, 
59, 66, 72, 81, 83 and 84. 
 
HPV clearance was defined as the absence of an HPV type that was present 
during previous visit. A total of 41.51% (44/106) women cleared HPV 
infections at second visit and 42.03% (29/69) women cleared HPV infections 
during third visit. At second visit, the most frequently cleared type was the 
LR-HPV 6 with 7.59% ( 6/79) and HPV types within the α3 species were the 
most frequently cleared with 22.78% (18/79) (Table 2.2). The most frequently 
cleared HR-HPV type was HPV 53 with 6.33% (5/79). 
 
HPV persistence was defined as the detection of an HPV type that was 
present at previous visit. HPV persistence was 48.11% (51/106) at second 
visit and 46.38% (32/69) at third visit. Both at second and third visit HR types 
were the most persistent HPVs; 62.37% (58/93) at second visit and 59.68% 
(32.38%) at third visit (Table 2.2). The persistence frequency of LR-HPV was 
37.63% (35.63) at second visit and 40.32% (25.62) at third visit. At both visits 
HPV 58 was the most persistent HR-HPV type with a frequency of 8.60% 
(8/93) at second visit and 11.29% (7/62) at third visit. The most persistent 
HPVs were from α9 species on both visits with a detection frequency of 
24.73% (23/93) at second visit and 27.42% (17/62) at third visit. 
 
2.4.9 HPV prevalence and type distribution according to cervical 
cytology 
Pap smear results were available for a total of 171 women. A total of 146/171 












abnormal cytology. Abnormal cytology consisted of 14 ASCUS and 7 LSIL. 
Overall, only 2.34% (4/171) specimens had invalid results due to specimen 
inadequacy. HPV prevalence in women with normal cytology was 65.75% 
(96/146) while in women with abnormal cytology the prevalence of HPV was 
80.95% (17/21). The prevalence of single HPV infection in normal cytology 
was 40.63% (39/96) and that of multiple HPV infections was 59.38% (57/96). 
In abnormal cytology consisting of 17 women with HPV infection and four 
women who are HPV negative inspite of having abnormal cytology results, 
the prevalence of single HPV infections was 17.65% (3/17) and that of 
multiple infections was 82.36% (14/17). There were few (n=17) study 
participants with abnormal cytology, therefore no further analysis could be 
reported on HPV prevalence according to cervical cytology. 
 
2.5 Discussion 
The study presented in this report is a longitudinal analysis of age-specific 
prevalence of HPV DNA in a population of young women from KwaZulu 
Natal. The baseline HPV prevalence in this study was 67.26% which is quite 
high considering the fact that this cohort consists of HIV negative women. 
When compared to women ≤30 years from another region in South Africa, 
the prevalence of HPV was higher in our study compared to 41.8% and 
52.78% observed among HIV negative women from Cape Town (Allan et al., 
2008; Marais et al., 2008; Mbulawa et al., 2010). HPV prevalence is known to 
vary by region and population subgroups due to sexual behaviour (Bruni et 
al., 2010; Clifford et al., 2005b; Dartell et al., 2012; De Vuyst et al., 2010; 
Dols et al., 2012; Menendez et al., 2010; Michala et al., 2012; Smith et al., 
2008; Ting et al., 2010; Thomas et al., 2004; Vinodhini et al., 2012). 
Therefore, the observed difference between our study and the studies 
conducted in Cape Town could be due to different methods used in selecting 
the study population and diversity of HPV DNA detection techniques used by 
the same laboratory.  
 
HPV prevalent trends reveal that the high HPV prevalence of 67.26% in this 












statistically similar to that of HIV positive women (77.27%; 85/110 ) from the 
study of Mbulawa et al (2010) (P=0.059). Although the P-values were not 
significant, they were approaching significance. An obstacle as to why the p-
values were not significant could be possibly due to the small number of HIV 
positive young women aged ≤30 years from the cohort of Mbulawa et al 
(2010). Among HIV positive women, the most frequently detected HPVs 
types were HPV 62 (23.53%); HPVs 45, 61 (18.82%); HPV 53 (17.65%); 
HPV 52 (16.47 %); HPV 70 (15.29%); HPV 54 (14.12%) and HPVs 16, 66, 84 
with 12.94% (Mbulawa et al., 2010). Whereas in the current study the most 
commonly detected HPV types were HPV 58, 62 (14.67%); HPV 61 (14.0%);  
HPV 51 (12.67%); HPV 16 ,52 (11.33%); HPV 53 (10.67%) and  HPV 68 
(10.00%) (Figure 2.3). Among HIV positive women from Cape Town and HIV 
negative women from the current study, the most frequently detected HPV 
type was HPV 62 followed by HPV 61. It has been reported that HPV 62 is 
overrepresented in HIV positive individuals (Riva et al., 2007). When HPV 
types were stratified according to species, the most frequently detected HPV 
species in our study was α3 (62.67%) (Table 2.2) whereas among HIV 
positive women from Cape Town the α3 (70.00%) was also the most 
commonly detected HPV species (Mbulawa et al., 2010). The frequency of 
single HPV infections within species in our study was α3 (11.70%) and α7 
(10.96). Among HIV positive women from Cape Town the frequency of single 
HPV infection within species was α3 (11.69%) and α7 (12.28%) (Mbulawa et 
al., 2010). Therefore it may be possible that the high prevalence of HIV 
infections in KwaZulu Natal which is the highest in South Africa (Moodley, 
2006) might be influencing the distribution of HPV types in the general 
population of KwaZulu Natal. However speculation about the distribution of 
HPV being influenced by HIV still need further investigation for clarification in 
order to stand valid. 
 
When the prevalence of HPV acquisition was stratified according to HPV 
status, we noted that women who were HPV negative at baseline were less 
likely to acquire new HPV infections at second visit and third visit compared 












in agreement with results reported elsewhere, whereby it was also noted that 
HPV negative women at baseline have a lower probability of acquiring new 
HPV infections during follow up compared to women that are HPV positive at 
baseline (Liaw et al., 2001; Rousseau et al., 2001). This may be due to the 
fact that an HPV positive status at enrolment could be an indication of a 
higher risk sexual behaviour (Rousseau et al., 2001). At third visit, the most 
frequently acquired HPV types were from the α3 species, similar findings 
have been reported elsewhere, that the risk of an incident HPV infection was 
greatest among α3 papillomavirus (Goodman et al., 2008).  
 
The most frequently cleared type was the LR-HPV 6 and other studies have 
also reported that LR-HPV types clears more rapidly compared to HR-HPV 
types (Datta et al., 2012; Goodman et al., 2008). Castle and others found that 
the number of cleared LR and HR-HPV types were higher than that of 
acquired types (Castle et al., 2005). This observation is in agreement with 
our results for only LR types at second visit and HR types at third visit. At 
second visit HPV types within the α3 species were the most frequently 
cleared and similar finding have been noted by other studies (Goodman et 
al., 2008). However at third visit the most frequently cleared HPV type was 
HPV 39 which is a HR type and collectively the most cleared HPV types were 
from the α7 species.  
 
Both at second and third visit HR types were the most persistent HPVs and 
this observation has been reported elsewhere (Datta et al., 2012; Rositch et 
al., 2012). It has been suggested that in order to estimate HPV persistence 
with the highest degree of accuracy, time interval should be narrowed down 
between visits to a month. This is due to the fact that more frequent testing 
intervals would detect transient infections that may be missed when testing 
with longer intervals (Rositch et al., 2012). The current study estimated HPV 
persistence between three month intervals and hence there may not be many 













When the prevalence of HPV was stratified according to age groups, we 
found that women aged 14-20 years had a higher HPV prevalence (69.23%) 
compared to women aged 21-30 years (65.55%), however the difference was 
not statistically significant. The observed trend is consistent with other 
studies stating that the highest prevalence of HPV is reported in young 
women then decreases thereafter with increasing age (Bruni et al., 2010; 
Castellsague et al., 2001; de Sanjose et al., 2007; Healey et al., 2001; Liaw 
et al., 2001; Menendez et al., 2010; McDonald et al., 2012; Smith et al., 
2008; Swangvaree et al., 2010; Thomas et al., 2000).  
 
When women were stratified according to cytology, a majority (85.38%) of 
women had normal cytology while a minority of women (12.28%) had 
abnormal cytology. This observation was influenced by the few number of 
cytological results from this study (n=171). It has been reported that in 
women younger than 30 years HPV infections are most likely to be 
associated with ASCUS or LSIL (Gage et al., 2012). As expected, HPV 
prevalence was higher in women with abnormal cytology 80.95% compared 
to women with normal cytology 65.75%. Unsurprisingly, the prevalence of 
HR-HPV type was higher in women with abnormal cytology than in women 
with normal cytology (Allan et al., 2008).  
 
It is known that the impact of HPV vaccines depends upon the distribution of 
HR-HPV in a given population (Adler et al., 2008), since HR-HPVs are a 
necessary causes of cervical cancer (Moscicki et al., 2006). In our current 
study the prevalence of HPV types targeted by the quadrivalent vaccine is as 
following, HPV 16 (11.33%); HPV 18 (8.00%); HPV 6 (9.33%) and HPV 11 
(1.33%). The vaccine has some degree of cross protection against HPV 31 
and HPV45 which are not present in the vaccine (Wheeler et al., 2009). The 
prevalence of HPV 31 is 4.00% and that of HPV 45 is 9.33%. Although the 
distribution of HPV types in women with normal cytology varies across the 
different regions of the world, it has been noted that HPV 16, 18, 31 and 58 
were consistently found among the 10 most frequent types in all regions 












five most frequently detected HR-HPV types among women with normal 
cytology are HPV 16, 52, 18, 58, and HPV 53 (Louie et al., 2009b; HPV 
Information Centre, 2009). However in our study, the most prevalent HR-HPV 
types in normal cytology in descending order were; HPV 58 (14.67%); HPV 
51 (12.67%);  HPV 52, 16 (11.33%); HPV 53 (10. 67%); HPV 68 (10.00%) 
and HPV 39, 45 (9.33%). Interestingly HPV 58 was also found to be the most 
prevalent HPV type among Zimbabwean women aged 18-49 years (Fukuchi 
et al., 2009). Several studies have proposed that this type should also be 
included in the HPV vaccine (Castellsague et al., 2001; Chan, 1999; Chan, 
2012; Zhang et al., 2010) since neoplastic lesions caused by this type are 
likely to progress to cervical cancer (Castellsague et al., 2001). 
 
Epidemiological data on HPV prevalence and type distribution at baseline is 
criticall to evaluate the impact of HPV vaccines (Bruni et al., 2010). 
Therefore, the data presented in this study serves as a starting point to help 
in the growing knowledge of understanding the burden of HPV infection. 
Hence, this data will be useful concerning policy making regarding to HPV 
screening that would maximize the potential benefits of an HPV vaccine 
(Marais et al., 2008; Smith et al., 2008). In general, the Pap smear is used to 
screen asymptomatic women and consequently this has lead to drastic 
reduction in the occurrence of cervical cancer in populations where there is 
wide coverage. In South Africa, women are recommended to have three 
smears every 10 years from the age of 30 years onwards. Internationally, 
women are recommended to have their first Pap smear taken within the first 
three years of sexual debut or at age 21 years annually until at the age of 30 
years. After the age of 30 years, women are then recommended to have their 
Pap smear taken every three years until the age of 65-70 years (Botha et al., 
2010). However screening women between ages 20-24 years has little or no 
effect on the incidence of cervical cancer in women younger than 30 years 
(Sasieni et al., 2009). In the current study there were only 12.57% (21/167) 
women with abnormal cytology and those women were aged 14-25 years. At 
the age of 30 a majority of these women will have cleared most of these 












women over the age of 30 years will be effective due to the fact that it will 
only be those women with persistent HR-HPV types in which lesions could 
progress and eventually lead to cervical cancer if not treated. 
 
2.6 Conclusion 
In conclusion, HPV prevalent trends reveal that the high HPV prevalence in 
this Durban cohort consisting of HIV negative women aged 14-30 years is 
similar to that of HIV positive women from Cape Town. Therefore, it could be 
possible that the high prevalence of HIV infections in KwaZulu Natal might be 
influencing the distribution of HPV types in the general population of KwaZulu 
Natal. 
 
We noted that women who were HPV negative at baseline were less likely to 
acquire new HPV infections at second and third visit compared to women 
that were HPV positive at baseline. We also noted that the LR-HPV 6 was 
the most frequently cleared type and that both at second and third visit HR 
types were the most persistent HPVs.  
 
When the prevalence of HPV was stratified according to age groups, we 
found that women aged 14-20 years had a higher HPV prevalence compared 
to women aged 21-30 years; however the difference was not statistically 
significant.  
 
The prevalence of HPV types targeted by the quadrivalent vaccine is as 
following, HPV 16 (11.33%); HPV 18 (8.00%); HPV 6 (9.33%) and HPV 11 
(1.33%) and that of HPVs 31 and 45 are 40.00 and 9.33%. Results from this 
study will inform policy makers about which HPV types are circulating in the 
country and will provide valuable data for assessing the impact of HPV 
vaccination programs in this country. However it should be noted that 
decisions on HPV types in vaccine should be based on HPV in cervical 
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An HPV genotype is defined as being more than 10% different from all others 
in their L1 gene sequence (Bernard et al., 2010; Chow et al., 2010; de Villiers 
et al., 2004). Genotypes occur in the form of numerous genomic variants that 
differ by 2% in most genes and 5% in less conserved regions (Bernard et al., 
2010; Ho et al., 1993a). The most variable region of the HPV genome is the 
LCR (Calleja-Macias et al., 2005; de Villiers et al., 2004; Schmidt et al., 
2001); this region is therefore the most appropriate for defining HPV variants.  
 
HPV 16 LCR variants are grouped into 5 distinct phylogenetic branches 
namely; Asian (As), Asian American (AA), African 1 (Afr1), African 2 (Afr2) 
and European (Eur) variant (Ho et al., 1993a; Mendoza et al., 2013; Tanzi et 
al., 2009; Yamada et al., 1997).  HPV 58 variants are divided into four 
lineages (A-D) based on nucleotide variation in the LCR. Lineage A is the 
most common branch and is divided into sublineages A1, A2 and A3. The B 
lineage is divided into B1 and B2, while lineage C is not divided. Lineage D is 
divided in D1 and D2 (Chen et al., 2011a; Godinez et al., 2013). HPV 53 
variants can be divided into two clusters which are termed prototype like (P-
L) and non prototype like (Non P-L) (Kocjan et al., 2007; Prado et al., 2005). 
 
Most studies that investigate HPV sharing and transmission between 
heterosexual partners, consider type-specific concordance which only 
evaluates sharing of one or more HPV genotypes between partners but not 
the variant shared (Abalos et al., 2012; Benevolo et al., 2008; Bleeker et al., 
2005; Burchell et al., 2011; Burchell et al., 2010; Castellsague et al., 1997; 
Giovannelli et al., 2007; Hernandez et al., 2008; Mbulawa et al., 2010; 
Mbulawa et al., 2009; Parada et al., 2010). Although this method of 
investigation is accurate, it is not precise and has the tendency to overstate 
HPV transmission between couples. Therefore the identification of HPV 
variants by sequencing enables one to investigate the transmission of HPV 
with a higher level of precision (Ho et al., 1993a; Lee et al., 2009). Only one 












and it was found that from a total of eight HPV 16 positive couples, variant 
concordance was found in only four couples (Ho et al., 1993a). 
 
In South Africa, there is only one study which analyzed HPV 16 variant 
distribution. In 93 Black South African women the Eur variant of HPV 16 was 
found to be the most common (47%) while the African variants (Afr1 and 
Afr2) were 41% of all isolates (Tu et al., 2006). No studies have analysed the 
prevalence of HPV 53 and 58 variants in the South African population.  
 
3.2 The aims of the study 
In this chapter we examined LCR sequence variation in HPV 16, 53 and 58 
positive heterosexual couples to determine which variants were present. The 
current study used samples from an HPV couples study cohort described by 
Mbulawa et al (2010) in which the role of factors that influence HPV 
prevalence was examined in 486 heterosexually active black South African 
couples. The ultimate goal of this study is to determine HPV variant-specific 
concordance of HPV types 16, 58 and 53 between partners in a couple. 
 
3.3 Materials and methods 
3.3.1 Description of cohort 
This study made use of stored specimens and data from an HPV couples 
cohort study (Mbulawa et al., 2010). The cohort participants were 486 
heterosexually active black couples with a mean age of 35 years ranging 
from 18 to 66 years. These participants were recruited from Empilisweni 
centre, Cape Town, South Africa. Cervical and penile specimens were 
collected every 6 months for 24 months. DNA was extracted from both penile 
and cervical specimens using the MagNA Pure Compact Nucleic Acid 
Isolation kit (Roche) and an automated MagNA Pure Compact machine 
(Roche).  
 
Type specific HPV concordance among couples was defined as the presence 












relationship.  A total of 10% of the HIV negative couples had concordant HPV 
types while 48% of HIV positive couples shared HPV types. In HIV discordant 
couples in which the male partner was HIV positive, 11% were HPV 
concordant while in HIV discordant couples where the female partner was 
HIV positive, 30% shared HPV types (Mbulawa et al., 2010). 
 
A total number of seventeen HPV 16 (Table 3.1), eight HPV 58 (Table 3.2) 
and sixteen HPV 53 (Table 3.3) concordant couples were identified from the 
study of Mbulawa et al (2010). Stored DNA specimens isolated from cervical 
and penile specimens from these couples were used in this study to analyse 
the variants of HPV 15, 53 and 58 based on the sequence of the LCR. 
 
Table 3.1 HPV 16 concordant couples identified using the Roche Linear Array Genotyping 
test (Mbulawa et al., 2010). 
Sample 
identity 
Gander Age HIV 
status 
HPV types cytology 
181-1 Female 28 - 16, 58 LSIL 
181-2 Male 32 - 16 - 
282-1 Female 19 - 16, 18 normal 
282-2 Male 26 - 16 - 
368-1 Female 46 + 16, 52 normal 
368-2 Male 63 + 6, 16, 35, 45, 53, 68, 70, 72, 83, 89 - 
440-1 Female 18 + 6, 16, 39, 45, 58, 59, 61, 62, 66, 73, 
81, IS39 
LSIL 
440-2 Male 22 - 6, 16, 45, 59, 61, 62, 81, 66 - 
460-1 Female 31 + 16, 58, 61, 66, 68, 69 normal 
460-2 Male 40 - 6, 16, 58, 61, 66, 68, 69 - 
501-1 Female 41 + 6, 16, 35, 39, 51, 53, 62, 66, 68, 72, 
73, 81 
ASCUS 
501-2 Male 37 + 16, 35, 53, 68 - 
511-1 Female 30 + 11, 16, 42, 58 LSIL 
511-2 Male 33 + 11, 16, 39, 42, 55, 58, 61, 68 - 
529-1 Female 35 + 16, 35, 51, 53, 55, 58, 62, 68, 81 ,84 HSIL 
529-2 Male 45 - 16, 35, 51, 53, 55, 58, 62, 68, 81 ,82 - 
571-1 Female 28 + 16,18, 52, 53, 55, 56, 61, 62, 72, 84, 
IS39 
LSIL 
571-2 Male 25 - 16,18, 45, 52, 53, 55, 56, 61, 62, 66, 
72, 84 IS39 
- 
605-1 Female 21 - 16 normal 
605-2 Male 25 - 16  
621-1 Female 33 + 16 LSIL 
621-2 Male 36 - 16, 53, 61 - 
626-1 Female 23 + 16, 52, 70, 84 normal 
626-2 Male 25 + 16, 45, 53, 66, 68, 70, 83 - 
727-1 Female 42 + 16, 53, 73, 81 LSIL 
727-2 
 


























744-1 Female 22 - 16, 31, 70 normal 
744-2 Male 26 + 11, 16, 59, 89 - 
763-1 Female 36 + 16, 40, 83 LSIL 
763-2 Male 29 - 16, 54, 61, 83, 84 - 
811-1 Female 30 - 16, 31, 35, 39, 45, 54, 55, 56, 62, 68, 
70, 72, 84 
LSIL 
811-2 Male 23 + 16, 18, 45, 51, 53, 54, 68, 69, 70, 84 - 
821-1 Female 41 + 16 HSIL 
821-2 Male 39 + 16, 62, 84 - 
 
Table 3.2 HPV 58 concordant couples identified using the Roche Linear Array Genotyping 
test (Mbulawa et al., 2010). 
Sample 
identity 
Gander Age HIV 
status 
HPV types cytology 
153-1 Female 38 + 58 LSIL 
153-2 Male 49 - 58, 62 - 
313-1 Female 39 + 26, 58 normal 
313-2 Male 40 + 26, 58 - 
460-1 Female 31 + 16, 58, 61, 66, 68, 69 normal 
460-2 Male 40 - 6, 16, 58, 61, 66, 68, 69 - 
511-1 Female 30 + 11, 16, 42, 58 LSIL 
511-2 Male 33 + 11, 16, 39, 42, 55, 58, 61, 68 - 
529-1 Female 35 + 16, 35, 51, 53, 55, 58, 62, 68, 81 ,84 HSIL 
529-2 Male 45 - 16, 35, 51, 53, 55, 58, 62, 68, 81 ,82 - 
623-1 Female 25 + 26, 58 LSIL 
623-2 Male 24 - 26, 58 - 
683-1 Female 36 + 51, 53, 58, 61, 83, 89 normal 
683-2 Male 29 + 51, 53, 58, 59, 61, 62, 83 - 
762-1 Female 30 + 33, 35, 42, 58, 61, 62, 68, 70, 71, 72, 
81, 83 
normal 




Table 3.3 HPV 53 concordant couples identified using the Roche Linear Array Genotyping 






HPV types cytology 
308-1 Female 45 + 53, 58 LSIL 
308-2 Male 49 + 53 - 
339-1 Female 19 - 53, 54 normal 
339-2 Male 21 - 53, 56, 59 - 
364-1 Female 25 + 31, 42, 45, 52, 53, 61, 62 ASCUS 
364-2 Male 29 - 31, 45, 52, 53, 54, 61, 62 - 
408-1 Female 28 - 53, 55, 61, 62, 71, 83, 84, 89 normal 
408-2 Male 34 - 53, 55, 59, 61, 62, 66, 70, 71, 83, 84, 89 - 
461-1 Female 25 + 39, 45, 53, 58, 83 normal 
461-2 Male 41 - 53 - 






































529-1 Female 35 + 16, 35, 51, 53, 55, 58, 62, 68, 81 ,84 HSIL 
529-2 Male 45 - 16, 35, 51, 53, 55, 58, 62, 68, 81 ,82 - 
547-1 Female 31 + 53, 61, 66, LSIL 
547-2 Male 32 - 42, 53, 56, 89 - 
571-1 Female 28 + 16,18, 52, 53, 55, 56, 61, 62, 72, 84, IS39 LSIL 
571-1 Male 25 - 16,18, 45, 52, 53, 55, 56, 61, 62, 66, 72, 84, IS39 - 
669-1 Female 47 + 16, 53, 83 ASCUS 
669-2 Male 30 - 39, 40, 53, 62, 66 - 
683-1 Female 36 + 51, 53, 58, 61, 83, 89 normal 
683-2 Male 29 + 51, 53, 58, 59, 61, 62, 83 - 
693-1 Female 37 + 33, 51, 53, 61, 62, 84 LSIL 
693-2 Male 45 - 31, 33, 51, 53, 61, 62, 84 - 
696-1 Female 27 + 6, 35, 53, 55, 62, 84 LSIL 
696-2 Male 36 - 35, 40, 53 - 
702-1 Female 27 + 53 normal 
702-2 Male 32 + 35, 52, 53, 58, 66, 67 - 
799-1 Female 25 - 53, 70 normal 
799-2 Male 35 + 53, 58, 62, 72, 84 - 
805-1 Female 36 + 52, 53, 62, 68, 83 LSIL 
805-2 Male 36 - 31, 45, 52, 53, 62, 66, 70, 72 - 
 
3.3.2 PCR amplification of HPV 16, 58 and 53 LCR 
A total number of seventeen HPV 16, eight HPV 58 and sixteen HPV 53 
positive couples were identified in the HPV couples cohort using the Roche 
Linear Array HPV Genotyping data from the study of Mbulawa et al (2010). 
To analyse the sequence variants of HPV genotypes 16, 53 and 58 in these 
specimens the LCR was amplified by PCR and sequenced. Primers specific 
to HPV 16, 58 and 53 LCRs were used to target their respective LCRs. The 
primers are shown in Tables; 3.4-3.6.  
Table 3.4 Primers used in the amplification of HPV 16 (Kurvinen et al., 2000) 
Primer name Sequence and length of primers Position  Length 
(bp) 
HPV16-LCR-F 5’-CCTCATCTACCTCTACAACTGCTAAACGC-3’ (29) 7108-7136 1028 
 HPV16-LCR-R 5’-CGTCGCAGTAACTGTTGCTTGCAGTACACAC-3’ (31) 222-192 
 
Table 3.5 Primers used in the amplification of HPV 58 (Chan et al., 2011) 
Primer name Sequence and length of primers Position  Length 
(bp) 
HPV58-LCR-out-F 5’-GATCAGTTTCCTTTGGGACG-3’ (20) 7017-7036 948 
HPV58-LCR-out-R 5’-ACCTCAGATCGCTGCAAAGT-3’ (20) 215-234 
HPV58-LCR-in-F 5’-CCTTAAAGCAAAGCCCAGAC-3’ (20) 7058-7077 













Table 3.6 Primers used in the amplification of HPV 53 (Prado et al., 2005) 
Primer name Sequence and length of primers Position  Length 
(bp) 
HPV53-LCR-F 5’-TTTGCATGTTGTTAATAAATA T-3’ (22) 7270-7291 602 
HPV53-LCR-R 5’-AGTAGGATTGTTACTTTC-3’ (18) 1-18 
 
PCR reactions for the amplification of the different LCRs of each HPV type 
were set up in a total volume of 25µl. The volumes and concentrations of 
PCR components were as follows: 500 nM of each primer mixed with 12.5μl 
of ImmoMix™ (Bioline, Massachusetts, USA) which is a mixture that consists 
of 2mM dNTP mix, IMMOLASE™ DNA polymerase enzyme, 32 mM 
(NH4)2SO4, 125 mM Tris-HCl (pH 8.3), Stabilizer, 0.02% Tween 20 and 
1.5mM magnesium salt to enhance enzyme activity. A total of 1μl DNA 
sample was added to each PCR. The ImmoMix™ cocktail contains a dNTP 
mixture consisting of the nucleotides (dCTP, dTTP, dATP and dGTP) for the 
extension of primers. The high-specific IMMOLASE™ DNA polymerase 
enzyme was used to efficiently amplify the LCR. For HPV 16 LCR 
amplification, the protocol was carried out according to Kurvinen et al (2000) 
with minor modifications: initial denaturation at 95°C for 7 minutes, 35 cycles 
consisting of 94°C for 1 minute, 56.5°C for 1 minute and 72°C for 2 minutes to 
allow for primer extension. Final extension was at 72°C for 10 minutes for the 
final elongation of primers.  
 
The amplification protocol for the LCR of HPV 58 was followed according to 
Chan et al (2011) with minor modifications. Thermal conditions for outer 
primers were as following; initial denaturation at 95°C for 7 minutes, 40 cycles 
consisting of 94°C for 30 seconds, 58°C for 30 seconds and 72°C for 1 minute 
to allow for primer extension. Final extension was at 72°C for 7 minutes for 
the final elongation of primers. Thermal conditions for inner primers were as 
following;  initial denaturation at 95°C for 7 minutes, 40 cycles consisting of 
94°C for 30 seconds, 60°C for 30 seconds and 72°C for 1 minute to allow for 
primer extension. Final extension was at 72°C for 7 minutes for the final 
elongation of primers. The amplification protocol for the HPV 53 LCR was 












an initial denaturation at 95°C for 7 minutes, followed by 40 cycles of 94°C for 
30 seconds, 55°C for 30 seconds and 72°C for 1 minute to allow for primer 
extension. Final extension was at 72°C for 7 minutes for complete synthesis 
of all the PCR products. Agarose gel electrophoresis of HPV 16, 58 and 53 
DNA was performed on 1% agarose gels at 80 volts for DNA fragments 
larger than one kilobase (kb). DNA separates on agarose gel according to 
size of DNA fragment. Electrophoresis of PCR amplicons less than one kb 
was carried out on 2% agarose gels at 100 volts. The separation of DNA 
fragments larger than 5kb was performed using 0.8% agarose gel. All 
agarose gels contained ethidium bromide at a concentration of 0.5µg/ml for 
DNA visualization on a UV transilluminator at 260nm (Syngene). 1X Tris-
Borate EDTA (TBE) was the buffer medium used for gel electrophoresis. 
DNA fragment size was estimated by using the one kb O’Gene Ruler (range 
250bp-10000bp) and 100bp O’Gene Ruler (range 100bp-1000bp) 
(Fermentas, USA) for large and small DNA fragments. 
 
Samples in which the LCR could not be successfully amplified using this 
method were non-specifically amplified by rolling circle amplification (RCA) 
as described in section 3.3.3. 
 
3.3.3 Rolling circle amplification of DNA for PCR 
Rolling circle amplification (RCA) was performed using the Illustra™ 
TempliPhi 100 Kit (Amersham Biosciences, GE Healthcare, UK). This is the 
most commonly used kit (Rector et al., 2004) and is most suitable to use 
when there is a tiny amount of starting DNA (Nelson et al., 2002). The 
advantages of using RCA to amplify HPV genome are that this technique is 
simple, rapid and efficient method for the non-specific enrichment of circular 
DNA (Johne et al., 2009; Marincevic-Zuniga et al., 2012). In addition to that, 
this technique does not make use of any special instrument to cycle the 
temperature except the PCR machine which is widely used for DNA 













The reactions were carried out according to manufacturer’s instructions. DNA 
specimens for amplification (1µl) were mixed with 5µl of sample buffer in a 
0.2ml thin wall PCR tube. The sample buffer contained exonuclease-
protected random hexamers. The mixture was heated at 95°C for 3 minutes 
to denature the double stranded (ds) DNA and cooled to 4°C. A premix of the 
TempliPhi enzyme mix (0.2µl), TempliPhi reaction buffer (5µl) and additional 
0.45µl 10mM dNTP were prepared in a separate tube. The enzyme mix 
contained the Φ29 DNA polymerase, extra dNTPs and extra hexamers in 
50% glycerol. The TempliPhi reaction buffer contained dNTPs and salts for 
enzyme activity. Five microlitres of the premix were added to the cooled 
sample and mixed by vortexing. The reaction was incubated at 30°C for 18 
hours on an AB9700 machine (Applied Biosystems).  
 
The amplification reaction was initiated when random hexamers hybridized to 
the circular DNA (Figure 3.1). The (Φ29) DNA polymerase extends each of 
the primers until it reaches the next primer downstream. The (Φ29) DNA 
polymerase then displaces the next downstream primers, rendering the 
dsDNA to single strand after displacement. The displaced single strand then 
acts as an available template to which more hexamers can anneal for further 
extension. The extension process results in the formation of dsDNA again. 
This process is repeated several times and results in the formation of 
repeated whole HPV genome sequences which are termed concatemers 
(Demidov, 2002; Johne et al., 2009; Nelson et al., 2002; Rector et al., 2004). 
This cycle can continue until the supply of free nucleotides are exhausted 
(Demidov, 2002; Nelson et al., 2002). 
 
The RCA was carried out for 18 hours, then the mixture was incubated at 
65°C for 10 minutes to inactivate the bacteriophage Φ29 DNA polymerase. 
This step was then followed by diluting the mixture by adding 30µl of HPLC 
water to each tube. Two microlitres of sample were electrophoresed on 0.8% 
agarose gel at 85 volts. From the RCA amplicons, the respective LCRs of the 












respective HPV types according to the former described protocols. The rest 
of sample was stored at -20°C for further use in subsequent reactions. 
Figure 3.1 A-D Schematic diagram depicting principle of rolling-circle amplification in circular 
genomes. Blue lines indicate target DNA sequence, green line depicts oligonucleotide 
primers and red lines represent new DNA synthesized by the polymerase. Random 
oligonucleotide primer anneal to circular DNA at multiple sites (A). DNA polymerase begins 
to synthesize complementary strand at the bound primer (B). The complementary DNA 
strand is extended until it reaches the next bound primer (C), where strand displacement 
occurs and DNA synthesis continues for additional cycles. Primers that are still present in the 
mixture continue to bind to the displaced strand. Consequently giving rise to additional 
initiation points. This process results to long concatemiric products of double-stranded DNA 
molecules (D) (Johne et al., 2009).  
 
 
3.3.4 DNA Sequencing and phylogenetic analysis 
The amplified LCR PCR products were checked for the presence of a unique 
HPV LCR band on an agarose gel. The PCR products were sent to 
Stellenbosch Central Analytical Facility (Stellenbosch University) where they 
were purified and sequenced directly using a Big Dye Terminator v3.1 Cycle 
sequencing kit in an ABI DNA sequencer 3130 (Applied Biosystems). The 
forward and reverse primers used for the PCR amplification were used for 
sequencing both strands of the amplicons.  
 
Sequences were aligned using Muscle (Edgar, 2004) and ambiguous 
alignments refined with GBlocks (Castresana, 2000). Phylogeny was 
estimated by maximum likelihood with PhyML 3.0 (Guindon et al., 2010) 
assuming a General Time Reversible (GTR) nucleotide substitution model 
and gamma distributed substitution rate among sites as the best fit for the 
LCR sequences (Chan et al., 2011; Sun et al., 2012).  Confidence was 
estimated by 1000 bootstrap replicates. 
Circular DNA genome
Random primers  
anneal to DNA














To confirm that sequence variations identified in the LCR were not as a result 
of Taq polymerase errors during amplification the PCR amplification and 
sequencing were independently repeated. 
 
3.4 Results 
3.4.1 PCR amplification of HPV 16, 58 and 53 LCR 
The LCR was successfully amplified in twelve out of the seventeen HPV 16 
positive couples. A representative agarose gel of the PCR products for eight 
male specimens is shown in Figure 3.2. The LCR was amplified in seven 
specimens; 181-2, 368-2, 440-2, 460-2, 501-2, 621-2 and 727-2 and not 
amplified in one specimen 605-2. The amplicon size was 1028bp and the 
same amplicon size was obtained from specimens 181-1, 368-1, 440-1, 460-
1, 501-1, 511-1, 511-2, 529-1, 529-2, 571-1, 571-2, 621-1, 626-1, 626-2, 727-
1, 811-1 and 811-2 (results not shown).  
Figure 3.2 Representative agarose gel electrophoresis of PCR products for the amplification 
of the HPV 16 LCR from clinical specimens. The expect size of the amplification product 
(1028bp) is indicated on the right hand side. Specimen numbers are indicated at the top of 
the gel. A negative control PCR which had water instead of template was included 
(Negative). The sizes of the DNA fragments in the DNA size marker (Marker) are indicated 





















The HPV 58 LCR was successfully amplified in all eight HPV 58 positive 
couples. A representative agarose gel is shown in Figure 3.3 with the PCR 
products from three female specimens 460-1; 511-1 and 529-1. The 
amplicon size was 948bp and the amplicons of the same size were obtained 
from the other thirteen specimens 153-1, 153-2, 313-1, 313-2, 460-2, 511-2, 
529-2, 623-1, 623-2, 683-1, 683-2, 762-1 and 762-2 (results not shown).  
Figure 3.3 Representative agarose gel electrophoresis of PCR products for the amplification 
of the HPV 58 LCR from clinical specimens. The expect size of the amplification product 
(948bp) is indicated on the right hand side. Specimen numbers are indicated at the top of the 
gel. A negative control PCR which had water instead of template was included (Negative). 
The sizes of the DNA fragments in the DNA size marker (Marker) are indicated on the left.  
 
The HPV 53 LCR was successfully amplified in twelve out of sixteen HPV 53 
positive couples. A representative agarose gel is shown in Figure 3.4, with 
the PCR products from six female specimens; five specimens were LCR 
positive and one specimen was LCR negative. The amplicon size was 602bp 
and the same amplicon size was obtained from the remaining nineteen HPV 
53 positive specimens 308-2, 339-1, 339-2, 364-1, 364-2, 408-1, 408-2, 461-
1, 461-2, 501-2, 529-1, 529-2, 571-2, 669-2, 683-1, 683-2, 696-2, 702-1 and 





















Figure 3.4 Representative gel picture of amplified HPV 53 LCR from clinical specimens after 
electropheresis. The expect size of the amplification product (602bp) is indicated on the right 
hand side. Specimen numbers are indicated at the top of the gel. A negative control PCR 
which had water instead of template was included (Negative). The sizes of the DNA 
fragments in the DNA size marker (Marker) are indicated on the left.  
 
HPV 16, 58 and 53 positive samples in which the LCR was not successfully 
amplified were subjected to non-specific amplification using RCA. 
Amplification products were analysed by agarose gel electrophoresis. As 
RCA forms concatemers of the amplified DNA the product is visible as a high 
molecular weight band that migrates to a position above the 8000 bp DNA 
size marker as indicated in Figure 3.5. All the specimens in which the LCR 
could not be efficiently amplified were successfully amplified by RCA. Figure 
3.5 shows results from five male’s (from 511-2 to 626) specimens that were 





















Figure 3.5 Representative agarose gel electrophoretic analysis of products of rolling circle 
amplification of DNA from clinical specimens. Specimen numbers are indicated at the top of 
the gel. Water was used as negative control. Positive control was the plasmid pUC 19 
plasmid. 
 
Following RCA, enriched specimens were used as templates for the 
amplification of the LCR for HPVs 16, 58 and 53 using the type-specific 
primers previously described. Non-specific amplification of the template or 
target sequence by RCA increased the template concentration allowing for 
efficient amplification of the LCR. This is illustrated in Figure 3.6, where a 
specimen was amplified using PCR only, and only a feint DNA band of the 
expected size (1028 bp) was visible (A). However when the same specimen 
was subjected to RCA prior to the LCR PCR (B) a bright band was observed 
following agarose gel electrophoretic analysis. 



















Figure 3.6 Representative gel picture of amplified HPV 16 LCR after electropheresis. The 
agarose gel picture on the left shows PCR amplified LCR from clinical specimen prior to 
rolling circle amplification (A). While the agarose gel picture on the right (B) shows PCR 
amplified LCR produced from RCA amplified specimen, both samples were from the same 
specimen. 
 
3.4.2 HPV 16 LCR sequence analysis 
All the amplicons were sequenced directly in order to identify nucleotide 
differences within the LCR in comparison to the prototype HPV 16 European 
variant. This study made use of the HPV 16 corrected European reference 
sequence (Eur) retrieved from Papillomavirus Episteme or PAVE published in 
GenBank with the accession number (NC_001526) (van Doorslaer et al., 
2013). The positions of nucleotide substitutions in the different variants 
identified are shown in Table 3.7.  The LCR was successfully amplified and 
sequenced in a total of 12/17 (70.6%) couples and revealed a total of 19 
different point mutations, including 10 transitions and 9 transversions.  
 
Common mutations were defined as mutations that occurred in ≥ ten isolates. 
A total of fourteen common mutations were observed. These mutations were 












C7669T, C7689A, C7764T, C7786T, G7826A, G7834T, A7837C, A7839G, 
and C31T (Table 3.7). 
 
Table 3.7 Nucleotide mutations identified within the LCR of HPV 16 











































































Base in HPV16R sequence C A A G C A G G C C A C C T G G A A C 19 
Variant Sample 
Identity 
                    
AA 181-1 T     C A A T A C T T   T    10 
181-2 T     C A A T A C T T   T    10 
Eur (I) 368-1        A            1 
368-2        A            1 
Afr2a (I) 440-1    C A C A A T A  T T  A T C G T 14 
440-2    C A C A A T A  T T  A T C G T 14 
Afr2a (I) 460-1    C A C A A T A  T T  A T C G T 14 
460-2    C A C A A T A  T T  A T C G T 14 
Afr2a (I) 501-1    C A C A A T A  T T  A T C G T 14 
501-2    C A C A A T A  T T  A T C G T 14 
Afr2a (II) 511-1   C  A C A A T A  T T C A T C G T 15 
511-2   C  A C A A T A  T T C A T C G T 15 
Eur 529-1                    0 
529-2                    0 
Eur (II) 571-1  C                  1 
571-2  C                  1 
Afr2a (I) 621-1    C A C A A T A  T T  A T C G T 14 
621-2    C A C A A T A  T T  A T C G T 14 
Eur 626-1                    0 
626-2                    0 
Afr2a (I) 727-1    C A C A A T A  T T  A T C G T 14 
Eur (I) 727-2        A            1 
Eur (II) 811-1  C                  1 
Afr2a (I) 811-2    C A C A A T A  T T  A T C G T 14 
Single nucleotide base differences within HPV 16 LCR variants in comparison to the 
European prototype sequence HPV 16R, GenBank accession number (NC_001526), 
retrieved from Papillomavirus Episteme or PAVE (van Doorslaer et al., 2013). Sample 
identity denotes the specimen number and the letters (I-II) refer to variations within the 
sublineage analysed in the various specimens. Total indicates the overall number of 
mutations in each specimen analysed. The green highlighted base pair positions denote the 
position where the most frequent mutation occurred among all the isolates. Red bases 
indicate novel mutations. 
 
The number of mutations in each isolate ranged from 0-15. The most 
common mutation was a transition point mutation G7521A (highlighted in 
Table 3.7), which was detected in 70.8% (17/24) of the specimens. We 












These two nt changes were at positions A7372C and T7807C both detected 
in Afr2a sublineages. 
 
There were some mutations observed in transcription factor binding regions 
of the LCR. A transversion mutation G7385C was observed in the 
glucocorticoid response elements (GRE) region in 41.67% (10/24) isolates 
from the Afr2a (I) variants. A transversions mutation G7489A found in the 
GRE transcriptional binding site in 58.33% (14/24). The mutations; A7485C, 
G7521A, C7786T and G7826A were found within the YY1 binding site. 
Transversion and transition mutations; A7729C and C7764T were detected 
at the nuclear factor 1 (NF1) transcription factor binding site. A transversions 
mutation C7689A was found in the TEF1 binding site, a transversions 
mutation G7834T was found in the octamer-binding factor 1 (Oct1) and the 
transition C31T was found in the Sp1 transcription factor (Lei et al., 2011; 
Mendoza et al., 2013; Tanzi et al., 2009; Pande et al., 2008; Pientong et al., 
2013). 
 
3.4.3 HPV 58 LCR sequence analysis 
All the amplicons were sequenced in order to identify mutations within the 
LCR in comparison to the HPV 58 prototype. This study made use of the 
HPV 58 prototype sequence published in GenBank with the accession 
number NC_001443/D90400 as the reference sequence (Cento et al., 2011; 
Chan et al., 2011; Chang et al., 2011; Liu et al., 2012; Raiol et al., 2009; Wu 
et al., 2009). The positions of mutated bases in the different variants 
identified are shown in Table 3.8.  The LCR was successfully amplified and 
sequenced in all eight couples. LCR sequence analysis revealed 30 different 














Table 3.8 Nucleotide mutations identified within the LCR of HPV 58 
Single nucleotide base differences within HPV 58 LCR variants in comparison to the prototype sequence HPV 58R, GenBank accession number 
NC_001443/D90400. Sample identity denotes the specimen number. Identical variants within the A2 lineage were grouped into subgroups I to III. 
Total indicates the overall number of mutations in each specimen analysed. The green highlighted base pair positions denote the position where the 
most frequent mutation occurred among all the isolate. Red bases indicate novel mutations. 







































































































Base in HPV 58R sequence G T A G T C T C C C T T G T A T T G A C G A T C C T G C 28 
Variant Sample 
Identity 
                             
A2 (I) variant 153-1         T          G          2 
A2 (I) variant 153-2         T          G          2 
B2 variant 313-1   C   T A   G     G  C A  A C G  G G  A A 14 
B2 variant 313-2   C   T A   G     G  C A  A C G  G G  A A 14 
C variant 460-1 T G G T C  A   G C G  G  G    A  G  G T C A A 18 
C variant 460-2 T G G T C  A   G C G  G  G    A  G  G T C A A 18 
A2 (I) variant 511-1         T          G          2 
A2 (I) variant 511-2         T          G          2 
A2 (II) variant 529-1        G T    A      G          4 
A2 (II) variant 529-2        G T    A      G          4 
A2 (I) variant 623-1         T          G          2 
A2 (I) variant 623-2         T          G          2 
C variant 683-1 T G G T C  A   G C G  G  G    A  G  G T C A A 18 
A2 (III) variant 683-2        G T          G    G      4 
C variant 762-1 T G G T C  A   G C G  G  G    A  G  G T C A A 18 












Common mutations were defined as mutations that occurred in ≥ seven 
isolates.  In most of the isolates from eight couples, we observed a total 
number of 9 common mutations. These mutations were at the following 
positions; T7207A, C7266T, C7284G, A7714G, C7730A, A7779G, C30G, 
G54A and C62A (Table 3.8). A total of four different point mutations were 
found in two different nucleotide positions. These mutations were transitions 
at A7186G and C52T, and within the same positions tranversions were found 
A7186C and C52G. The number of mutations in each isolate ranged from 2-
18. The most common mutations were transitions point mutations C7266T 
and A7714G (highlighted in Table 3.8), which were detected in 56.3% (9/16) 
of the specimens.  
 
There were two nt changes that have not been reported before. These nt 
changes occurred in the following positions; C7199T and T7786G. Among 
the two nt changes; C7199T was detected in B2 variant while T7786G was 
detected in only one out of nine A2 variant which was termed A2 (III) variant. 
Only one mutation was observed in transcription factor binding regions of the 
LCR.  A transition mutation A7714G was observed at the NF1 transcription 
factor binding site (Raiol et al., 2009). 
 
3.4.4 HPV 53 LCR s quence analysis 
All the amplicons were sequenced in order to identify mutations within the 
LCR in comparison to the prototype HPV 53. This study made use of the 
HPV 53 prototype sequence published in GenBank with the accession 
number X74482 as the reference sequence (Cento et al., 2012; Kocjan et al., 
2007; Wyant et al., 2011). The positions of all mutated bases in the different 
variants identified are shown in Table 3.9.  The LCR was successfully 
amplified and sequenced in a total of (12/16; 75%) couples. LCR sequence 
analysis revealed 29 different point mutations in 34 nucleotide positions, with 













Common mutations were defined as mutations that occurred in ≥ 12 isolates. 
In most of the isolates from the twelve couples, we observed 19 mutations 
common. These mutations were at the following positions; T7422A, C7428T, 
C7432G, G7508A, T7528C, TGGGA insertion between 7530 and 5731, 
G7531A, T7538C, T7618G, T7619C, T7634C, A7655G, C7676G, C7685T, 
C7756T, G7758A, C7784T, A7797C and C7810T (Table 3.9). The most 
common mutations was a transitions point mutation at position G7508A 
(highlighted in Table 3.9), which was detected in all of the specimens. There 
were a total of nine nt changes and five deletions that have not been reported 
before. These nt changes occurred in the following positions; A7398G, 
A7566G, G7608A, T7609G, G7656T, T7709G, A7751G, T7760C, A7766G 
and deletions at the following positions; A7533, T7534, A7535, T7536, 
C7537. Among the nine nt changes (5/9 55.56%); A7398G, G7608A, 
T7609G, G7656T, A7751G and all five deletions; A7533, T7534, A7535, 
T7536, C7537 were detected in (non P-L) (IV) variants. Mutation at position 
A7566G was detected in prototype-like (P-L) (II) variants. Another nt change 
at position T7709G was detected in the non P-L (II) variants. The mutation 
T7760C was detected in both the non P-L (I) and non P-L (V) variants. 
Another mutation A7766G was also detected in the non P-L (V) variants. 
 
There were some mutations observed in transcription factor binding regions 
of the LCR. Mutations T7422A and G7508A were found in the YY1 binding 
site, mutations T7528C and C7810T were found in the E2 binding site. The 
following three nucleotide substitutions; A7655G, C7756T and G7758A were 
found in NF-1binding site while T7538C and T7648G were found in the Oct-1 












Table 3.9 Nucleotide mutations identified within the LCR of HPV 53 





































































































































Base in HPV53R sequence A T C C G T - - - - G A T A T C T A G T T T T T A G C C T A C G T A C A C 29 
Variant Sample 
Identity 
                                      
P-L (II) 308-1     A             G                    2 
308-2     A             G                    2 
P-L (I) 339-1     A                                 1 
339-2     A                                 1 
Non P-L (I) 364-1  A T G A C T G G G A      C    G C C  G  G T   T A C  T C T 23 
364-2  A T G A C T G G G A      C    G C C  G  G T   T A C  T C T 23 
Non P-L (II) 408-1  A T G A C T G G G A      C    G C C  G  G T G  T A   T C T 23 
P-L (I) 408-2     A                                 1 
Non P-L (III) 461-1  A T G A C T G G G A      C    G C C  G  G T   T A   T C T 22 
P-L (I) 461-2     A                                 1 
P-L (III) 501-1     A                  C     T          3 
501-2     A                  C     T          3 
Non P-L (III) 529-1  A T G A C T G G G A      C    G C C  G  G T   T A   T C T 22 
529-2  A T G A C T G G G A      C    G C C  G  G T   T A   T C T 22 
Non P-L (III) 571-1  A T G A C T G G G A      C    G C C  G  G T   T A   T C T 22 
571-2  A T G A C T G G G A      C    G C C  G  G T   T A   T C T 22 
Non P-L (IV) 669-1 G    A C T G G G A - - - - -   A G G C C G G T  T  G T A   T  T 27 
669-2 G    A C T G G G A - - - - -   A G G C C G G T  T  G T A   T  T 27 
Non P-L (I) 683-1  A T G A C T G G G A      C    G C C  G  G T   T A C  T C T 23 
683-2  A T G A C T G G G A      C    G C C  G  G T   T A C  T C T 23 
P-L (II) 696-1     A             G                    2 
696-2     A             G                    2 
Non P-L (V) 702-1  A T G A C T G G G A      C    G C C  G  G T   T A C G T C T 24 
702-2  A T G A C T G G G A      C    G C C  G  G T   T A C G T C T 24 
Single nucleotide base differences within HPV 53 LCR variants in comparison to the prototype sequence HPV 53R, GenBank accession number 
X74482. Sample identity denotes the specimen number and the letters (I-V) refer to changes within the variants analysed in the various specimens. 
Total indicates the overall number of mutations in each specimen analysed. The green highlighted base pair positions denote the position where the 












3.4.5 Phylogenetic classification of HPV 16, 58 and 53 variants  
HPV 16, 58 and 53 phylogenetic trees were generated in order to classify the 
LCR sequences into their respective lineages. Reference sequences for the 
respective HPV variants were obtained from GenBank. The LCR sequence 
alignments are included in the appendix (Figures 1-3). 
 
Reference sequences for HPV 16 LCR representing different phylogenetic 
branches/lineages were as following; AF402678 (AA), AF534061 (As), 
AF472508 (Afr1), AF472509 (Afr2) and prototype (Eur) reference sequence 
retrieved from Papillomavirus Episteme or PAVE (van Doorslaer et al., 2013). 
From the phylogenetic tree, 4 distinct lineages were observed and these 
corresponded to AA, Afr1, Afr2 and Eur-As variants (Figure 3.7), similar 
observations were noted elsewhere (Tanzi et al., 2009).  
 
The HPV 16 variants identified in this study were separated into distinct 
lineages based on the presence of diagnostic single nucleotide 
polymorphisms (SNPs) and phylogenetic analysis. Several diagnostic SNPs 
within the HPV 16 LCR and E6 genes have been identified that can be used 
to specifically distinguish some of the variant lineages (Cornet et al., 2012). 
The diagnostic SNPs covered by the LCR PCR products in this study are 
given in Table 3.10 (Cornet et al., 2012). The major European-Asian branch 
of HPV 16 variants can be distinguished from the African and Asian-
American branches by three LCR nucleotide positions (G7489, C7764 and 
C7786). These SNPs were present in the LCR sequences from samples 368-
1, 368-2, 529-1, 529-2, 571-1, 571-2, 626-1, 626-2, 727-2 and 811-1. The 
classification of the HPV 16 variants from these samples as belonging to the 
Eur-Asian lineage is well supported by the maximum-likelihood tree in Figure 
3.7 While the Eur lineage cannot be distinguished by any SNPs, the As 
lineage has six diagnostic SNPs in the LCR (T7177C, T7201C, C7270T, 
A7287C, G7842A/T and C24T). The HPV 16 LCR sequences for 368-1, 368-
2, 529-1, 529-2, 571-1, 571-2, 626-1, 626-2, 727-2 and 811-1 (covering nts 
7308-31) do not have G7842A/T and C24T typical of As, and were therefore 












Table 3.10 Diagnostic and common single nucleotide polymorphisms in the long control 
region of HPV 16 (modified from Cornet et al., 2012).  
aIncludes only nucleotide positions that can distinguish at least two of the nine identified 
sublineages from each other. Dashes indicate no nucleotide exchange from the HPV16 
reference sequence. Nucleotides separated by a slash are different nucleotides that can be 
in the given position for the given sublineage. Diagnostic SNPs are in boldface.bEAS, 
European-Asian; EUR, European; As, Asian; AFr, African; NA, North American; AA, Asian-
American. 
 
The major African branch can be specifically distinguished from the 
European-Asian branch by the presence of a C31T SNP in the LCR. This 
SNP was found in the LCR sequences for specimens 440-1, 440-2, 460-1, 
460-2, 501-1, 501-2, 511-1, 511-2, 621-1, 621-2, 727-1 and 811-2. The 
classification of the HPV 16 isolates from these samples clustered into the 
African lineage and is well supported by the maximum-likelihood tree in 
Figure 3.7. The two Afr sublineages (Afr1 and Afr2) can be separated based 
on four SNPs in the LCR, where the Afr2 lineage uniquely has A7485C, 
C7669T, G7826A and A7837C (Cornet et al., 2012). These SNPs were found 
in the LCR sequences for 440-1, 440-2, 460-1, 460-2, 501-1, 501-2, 511-1, 
511-2, 621-1, 621-2, 727-1 and 811-2, and they were therefore classified as 
Afr2. The presence of the diagnostic SNP A7839G in these LCR sequences 
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As C — — — — — — — — — — — C — — — — — — — A
/
T 
— — T — — 
AFr1 Afr1a - — — — — — — A — — A — — — T T — T — — — —
/
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— — — T 
Afr1b - — C — — — — A — — A — — — T T — T — — — A — — C T 
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/
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— — — T T A —
/
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C G — — — — — T 
Afr2b - — — — — — C A — T A — — — T T A T C — — — — — — T 
NA/AA NA - — — — — — C A — T A —
/
C 
— — T T — T — — — — — — — — 
AA1 - T — T T — C A — T A C — G T T — — — — — — G — — — 
AA2 - T — T —
/
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further allowed classification into the Afr2a sublineage. Although the HPV 16 
isolates from 511-1 and 511-2 could be classified as Afr2a based on 
diagnostic SNPs the LCR sequence had two additional nucleotide changes 
not present in the Afr2a reference sequence (A7372C and T7807C) and they 
therefore clustered separately in the phylogenetic tree (Figure 3.7). The LCR 
sequences from couple 181 clustered with the Asian-American reference 
sequence in the phylogenetic tree (Figure 3.7) and while no SNPs in the LCR 
can specifically distinguish AA variants (Cornet et al., 2012) they have the six 
SNPs common to this lineage (A7485C, G7489A, C7669T, C7689A, C7764T 
and C7786T).  
 
HPV 16 phylogenetic classification of LCR variants revealed that the majority 
half (12/24) of HPV 16 variants belonged to the Afr2a sublineage and 41.67% 
(10/24) Eur lineage while only 8.33% (2/24) belonged to the AA lineage. 
None of the LCR sequences identified in this study belonged to the As and 
Afr1 branch. 
 
HPV 58 LCR reference sequences representing different phylogenetic 
lineages were as following; HQ339045 (A1), HQ338950 (A2), QH339150 
(A3), HQ339176 (B1), HQ339309 (B2), HQ339310 (C), HQ338954 (D1) and 
HQ339312 (D2). HPV 58 phylogenetic tree revealed 4 distinct branches, 
namely branch (A) divided into A1, A2, A3; branch (B) subdivided into B1 and 
B2, branch (C) and finally branch (D) subdivided into D1 and D2 (Figure 3.8). 
The HPV 58 variants identified in this study were separated into distinct 
lineages based on the presence of diagnostic SNPs and phylogenetic 
analysis. Chan and co-workers (2011) identified several diagnostic SNPs or 
signature sequences in the LCR that can be used to separate the A1, A2, A3, 
B1, B2, C, D1 and D2 lineages of HPV 58 (Table 3.11). A maximum 
likelihood phylogenetic tree was generated using the LCR sequences from 














Table 3.11 Diagnostic and common single nucleotide polymorphisms in the long control 
region of HPV 58 (modified from Chan et al., 2011).  
A dash indicates the same nucleotide as in the prototype sequence. IN, indicates an 
insertion of 12 bp. for S5, 67% isolates have C and 33% have G; for K6, 86% isolates have G 
and 14% have T; for R7, 78.6% isolates have A and 21.4% have G; for R8, 96% isolates 
have G and 4% have A; for R9, 86% isolates have G and 14% have A; and for K10, 67% 
isolates have T and 33% have G. 
 
The majority of the LCR sequences (9/16) belonged to the A2 lineage. The 
LCR from couples 153, 511, 529, 623 and sample 683-2, clustered with the 
A2 reference sequence (Figure 3.8) and had the signature sequence for the 
A2 lineage (C7266T, (A/C)7714G). This lineage is known to dominate in 
Africa (Chan et al., 2011). Additional SNPs were present in the LCR from 
couple 529 (C7265G and G7421A) and 683-2 (C7265G and T7786G). A total 
of five of the LCR sequences clustered with the lineage C reference 
sequence in the phylogenetic tree (couples 460 and 762 as well as sample 
683-1) and had the SNPs diagnostic for this lineage (C7284G, T7345C, 
T7369G, C7730A, A7779G, C30G and C52T). The LCR from the remaining 
couple (313) clustered with the B2 lineage (Figure 3.8) and had the 
diagnostic SNPs for this lineage (C7284G, C7730A, G7745C, A7779G, 
C30G, and C52G). 
 
Two reference HPV 53 sequences were used for the construction of HPV 53 












The reference sequence X74482 was used to represent the prototype branch 
and AY949073 sequence was used to represent the non-prototype branch 
(Kocjan et al., 2007). The HPV 53 LCR phylogenetic tree revealed three 
separate branches based on the LCR (Figure 3.9).  Half 50% (12/24) of HPV 
53 analysed sequences belonged to the non P-L branch whereas 41.67% 
(10/24) sequences belonged to the P-L branch. Two sequences from couple 
669 belonged to a separate group in with significant bootstrap values. 
 
The two clusters of variants (non P-L and P-L) can be distinguished by a 4bp 
(TGGG) insertion at position 7530 in the LCR of non-protypelike variants 
highlighted in green (Figure 3.10).  This insertion was present in the majority 
58.33% (14/24) of the LCR couples; 364, 529, 571, 683, 702 and samples 
408-1 and 461-1. The LCR from couple 669 had a novel deletion of 5 bases 
at positions 7533-7537 highlighted in green that has not been reported to 

















Figure 3.7 Maximum likelihood phylogenetic tree of LCR sequences (645 nts) from HPV 16 
positive couples. Bootstrap support for the unrooted tree is shown as a percentage of 1000 
replicates, with values greater than 70% shown. (A) The LCR reference sequences for the 
different lineages were retrieved from GenBank with the following accession numbers (Afr1 
(AF472508) Afr2 (AF472509), As (AF534061), AA (AF402678). The corrected European 
reference sequence (Eur) was retrieved from Papillomavirus Episteme or PAVE (van 
Doorslaer et al., 2013). (B) The same tree with branches with less than 40% support 
collapsed and branch length ignored. Arrows indicate the position of isolates from couples 






















Figure 3.8 Maximum likelihood phylogenetic trees of LCR sequences (706 nts) from HPV 58 
positive couples. Bootstrap support for the unrooted tree is shown as a percentage of 1000 
replicates, with values greater than 70% shown. (A) The LCR reference sequences for the 
different lineages were retrieved from GenBank with the following accession numbers; 
HQ339045 (A1), HQ338950 (A2), QH339150 (A3), HQ339176 (B1), HQ339309 (B2), 
HQ339310 (C), HQ338954 (D1) and HQ339312 (D2). (B) The same tree with branches with 
less than 40% support collapsed and branch length ignored. Arrows indicate the position of 


















Figure 3.9 Maximum likelihood phylogenetic tree of LCR sequences (417 nts) from HPV 53 
positive couples. Bootstrap support for the unrooted tree is shown as a percentage of 1000 
replicates, with values greater than 70% shown. (A) The LCR reference sequences for the 
different lineages were retrieved from GenBank with the following accession numbers; 
X74482 (P-L) (Prototype-Like) and AY949073 (Non (P-L) Prototype-like). (B) The same tree 
with branches with less than 40% support collapsed and branch length ignored. Arrows 















Figure 3.10 HPV 53 diagnostic single nucleotide polymorphisms (SNPs) distinguishing the 
P-L variants from non P-L variants. Non P-L variants have a T7528C nucleotide substitution, 
4bp (TGGG) insertion at position 7530 and a T7538C in the LCR. Couple 669 had a unique 
five bases deletion at positions 7533-7537. 
 
3.4.6 HPV 16 variants in couples 
Of the 12 couples sharing HPV 16, ten were variant-specific concordant, 
sharing the same variant. The analysis of LCR variants showed that the 
majority (5/12; 41.7%) of couples shared the Afr2a sublineage. From the five 
couples sharing the Afr2a sublineage, four couples (440, 460, 501 and 621) 
were concordant with the Afr2a (I) sublineage. While partners in couple 511 












difference between the two Afr2a (I) and Afr2a (II) sublineage is that, Afr2a (I) 
has the mutation G7385C while Afr2a (II) has A7372C and T7807C.  Couple 
181 were found to share the AA variant. 
 
Four out of twelve (4/12; 33.3%) couples were concordant with the Eur 
lineage. Both partners in couples 529 and 626 were concordant with the Eur 
prototype variant. Couple 368 were concordant with the Eur (I) variant and 
the partners in couple 571 shared the Eur (II) variant. The difference between 
Eur (I) and Eur (II) variant is that, Eur (I) has a mutation at the position 
G7521A, while Eur (II) has a mutation at position A7314C.  
 
Two couples (2/12; 16.7%) were found to be discordant. The male partner in 
couple 727 had the Eur (I) variant while his respective female partner has the 
Afr2a (I) variant. In couple 811 the male partner had the Afr2a (I) variant 
while his female partner had the Eur (II) variant (Figure 3.7). 
 
3.4.7 HPV 58 variants in couples 
Of the eight couples sharing HPV 58, seven were variant-specific 
concordant, sharing the same variant. The phylogenetic classification of HPV 
58 LCR variants showed that half (4/8; 50%) of the couples shared the A2 
lineage. Partners in three couples; (153, 511 and 623) were concordant with 
the A2 (I) variant.  Partners in couple 529 both had the A2 (II) variant. The 
difference between the two A2 variants is that, the A2 (II) has two extra 
mutations at positions C7265G and G7421A.  
 
Partners in couples 460 and 762 (2/8; 25%) were concordant with the C 
variant and partners in couple 313 (1/8; 12.5%) were concordant with the B 
variant. The only HPV 58 variant discordant couple was couple 683; here the 
female partner had the C variant, while her male partner had the A2 (III) 
variant. The A2 (III) variant differs from the A2 (II) variant by having a 













3.4.8 HPV 53 variants in couples 
Of the 12 couples sharing HPV 53, ten were variant-specific concordant, 
sharing the same variant. The phylogenetic classification of HPV 53 LCR 
variants showed that (6/12; 50%) of couples shared the non P-L lineages. 
From the six couples sharing the non prototype-like lineage; partners from 
couples 364 and 683 shared the non P-L (I) variant.  Partners in two other 
couples; 529 and 571 were concordant with the non P-L (III) variant. In 
couple 669, partners were concordant with the non P-L (IV) variant and finally 
in couple 702 shared the non P-L (v) variant. The non P-L (I) variant differs 
by the mutation T7760C to the non P-L (II) variant which has T7709G 
mutation. The non prototype-like (I) variants differs by one extra/additional 
mutation in the position T7760C which is absent in the non P-L (III) variant.  
The non P-L (IV) variant is clearly distinguishable from all other non P-L 
variant in numerous positions. Among these positions are the mutations 
A7398G, five deletions at positions (A7533, T7534, A7535, T7536, C7537), 
G7608A, T7609G, T7648G, G7656T and A7751G. The non P-L (V) variant 
differs by one extra nucleotide at position A7766G from the non P-L (I) 
variant. 
 
Four couples (4/12; 33%) were concordant with the P-L lineages, and in 
these four couples; pa tners in couple 339 were concordant with the P-L (I) 
variant. Partners in couples; 308 and 696 were concordant with the P-L (II) 
variant. Partners in couples 501 shared the P-L (III) variant. The P-L (II) 
variant differs by an extra/additional mutation at position A7566G from the P-
L (I) variant. The P-L (III) variant differs to the P-L (I) variant by two 
extra/additional mutations at positions T7634C and C7685T. 
 
Two couples were HPV-58 variant specific discortdant. Partners in couples 
408 and 461 were discordant, with the female partner in couple 408 having 
the non P-L (II) variant while her respective male partner has the P-L (I) 
variant. Lastly in couple 461 the female partner had the non P- L (III) variant 












3.4.9 HPV variants stratified according to cervical cytology 
The HPV 16, 58 and 53 variants found in the cervical samples are 
summarised in Table 3.12 together with the cervical cytology data. A total of 
25 females were investigated for HPV 16, 58 and 53 variants. A total of 
nineteen women had single HPV type variant detected, five women had two 
HPV type variants detected; and the respective women had normal, ASCUS 
or LSIL. Only one woman (highlighted in green) had variants of all three HPV 
types investigated and was diagnosed with HSIL (Table 3.12). 
 
Table 3.12 HPV types 16, 58 and 53 variant distribution according to cervical cytology  
 
3.5 Discussion 
The analysis of sequence variants of HPV16 in this study revealed the 
presence of African 2a, Asian American and European variants in these 
South African men and women, with the African lineage, as expected, being 
the most prevalent. None of the HPV 16 variants belonged to the African1, 
Asian and North American lineages/sublineages. Since we only sequenced a 
Female partner HPV types HPV variant Cervical cytology 
313-1 58 B2 Normal 
339-1 53 P-L Normal 
368-1 16 Eur Normal 
408-1 53 Non P-L Normal 
460-1 16 58 Afr2/C Normal 
461-1 53 Non P-L Normal 
626-1 16 Eur Normal 
683-1  53 58 C/non P-L Normal 
702-1 53 Non P-L Normal 
762-1 58 C Normal 
364-1 53 Non P-L ASCUS 
501-1 16 53 Afr2/P-L ASCUS 
669-1 53 Non P-L ASCUS 
153-1 58 A2 LSIL 
181-1 16 AA LSIL 
308-1 53 P-L LSIL 
440-1 16 Afr2 LSIL 
511-1 16  58 Afr2/A2 LSIL 
571-1 16  53 Eur/non P-L LSIL 
621-1 16 Afr2 LSIL 
623-1 58 A2 LSIL 
696-1 53 P-L LSIL 
727-1 16 Afr2 LSIL 
811-1 16 Eur LSIL 












partial region of the LCR we were unable to precisely rule out the presence of 
the North American sublineage in our study. This is because in order to 
identify the North American sublineage we would also have to additionally 
include the E6 region, since the E6 is needed to identify North American 
sublineage (Tanzi et al., 2009, Yamada et al., 1997). This study is in 
agreement with the observation that, although HPV 16 phylogenetic analyses 
show a trend towards ethnogeographic separation of variants, some variants 
do exist in other regions; although not as prevalent as in their original 
geographic location (Tu et al., 2006). The observed phenomenon may be 
due to human migrations (Ho et al., 1993b; Stewart et al., 1996; Yamada et 
al., 1997). 
 
HPV 58 phylogenetic tree revealed 4 distinct lineages (A-D) with some 
lineages further subdividing into smaller branches and similar results have 
been reported elsewhere (Chan et al., 2011). Phylogenetic tree of HPV 58 
showed that 56.25% of HPV 58 LCR belonged to the A lineage, specific to 
A2 sublineage. Lineage A is has been shown to be the most prevalent 
lineage with the A2 sublineage being the most common (Chan et al., 2011). 
 
HPV 53  variants have been found to cluster into two distinct branches 
(Cento et al., 2012; Kocjan et al., 2007; Oliveira et al., 2012; Prado et al., 
2005; Wyant et al., 2011). However we identified a novel sublineage (from 
couple 669) with a unique five bases deletion at positions 7533-7537 that 
formed a new branch.  
 
In the only published study to have determined HPV variant concordance in 
couples, Ho and co-workers (1993) revealed that HPV 16 variants were 
shared in four out of eight couples. Variants in the other four couples were 
discordant (Ho et al., 1993a). In this study a high level of variant specific 
concordance was observed between sexual partners due to the fact that HPV 
16 and HPV 53 variants were shared in ten out of twelve couples. HPV 58 













In couples that were discordant for HPV variants, there are several possible 
explanations as to why the partners in those couples have discordant 
variants. One possible explanation is that both partners could have been 
initially infected by different variants that have established themselves to 
exclude other late arriving variants. Another possible explanation is that the 
former or latter variant may be latent (Ho et al., 1993a). A similar 
phenomenon was noted in a study done by Jiang et al (2009) where the 
genomic diversity of HPV 16 variants was determined from two specimens 
obtained from one individual at different time intervals.  At enrolment ten 
clones were analysed and sequencing results showed that eight clones 
contained identical sequences to the Eur variant. The remaining two clones 
contained different variations of the Eur-Afr2 sequence. Although the 
mutations in the two clones were similar and corresponded significantly to 
some base positions found in LCR of Afr2 variants. However the remaining 
E6 regions of the recombinants were identical to the Eur variant and 
therefore the Eur-Afr2 recombinants were considered to be Eur variants. At 
the second visit, 20 months later, neither the Eur variant nor the Eur-Afr2 
recombinants were detected, instead only the Afr2 variant was detected. A 
possible explanation of the disappearance of the Eur variant as well as the 
recombinants may be due to clearance of the variants or suppression to a 
low level below detectable threshold. The detection of the Afr2 variant during 
the follow up sample may represent reactivation of a latent infection. 
Alternatively the infection may represent a separate infection that might have 
been acquired from the concurrent or different sex partner (Jiang et al., 
2009).  
 
The LCR contains transcription factor binding sites which activate 
transcription of the E6/E7 oncogenes (Hoppe-Seyler et al., 1991; Sibbet et 
al., 1995). Mutations occurring in the LCR may interfere with the activities of 
transcription factors which could potentially have significant role in 
tumorigenesis (Stephen et al., 2000). Therefore sequence variations in LCR 
could possibly enhance viral oncogenes expression and represent risk 












factor binding site to virulence of the different HPV variants has been 
reported (Chansaenroj et al., 2012). It has been shown that overexpression 
of transcriptional factors such as octamer-1 (Oct-1) inhibit the promoter 
activities of HPV 16 and 18 (Hoppe-Seyler et al., 1991; Sibbet et al., 1995). 
HPV GRE has the ability to regulate the transcription of E6/E7 oncogenes 
(Chan et al., 1989). YY1 interferes and may prevent the LCR activity 
responsible for the expression of the E6/E7 oncogenes (Park et al., 1999; 
Stephen et al., 2000). NF1 plays a role in viral gene expression by activating 
viral regulator elements (Baldwin et al., 2007; Chen et al., 1996b). In essence 
mutation in the above mentioned transcriptional binding sites maybe the 
reason to why some variants have higher oncogenic potential compared to 
other variants. In this study mutations were found in the following 
transcriptional binding sites of HPV 16; GRE, YY1, NF1, TEF1, Oct1 and 
Sp1. Mutations were found in the following transcriptional binding sites of  
HPV 53; YY1, E2 binding site, NF-1binding site, Oct-1 and AP-1. Only one 
mutation was found in HPV 58 transcriptional binding site and that was at 
NF1. The effects of these mutations on the promoter activity of the LCR could 
be assessed using a luciferase reporter assay. By doing so, it would enable 
us to determine if these mutations result in different promoter activity. 
Differences in promoter activity may reflect differences in the transcription of 




Nucleotide variations in the LCR of HPV types; 16, 58 and 53 can be used to 
investigate the transmission of HPV between sexual partners. This is 
because comparison of these HPV infections in couples confirms the efficient 
sexual exchange of variants. Ten of twelve couples analysed were 
concordant for HPV 16 lineages. Seven of eight couples were concordant for 
HPV 58 lineages and ten of twelve couples were concordant for HPV 53 
lineages. HPV sharing between partners may be lower than reported due to 












One out of eight couples was discordant for HPV 58 lineages and two out of 
twelve couples were discordant with HPV 53 lineages. Therefore future 
studies need to additionally focus on HPV variant concordance when 
assessing the transmission of HPV instead of only focussing on type-specific 
HPV concordance. In addition, more samples need to be analysed for each 
couple to detect rare/low copy number variants. 
 
Further studies need to have a large enough sample size to further 
investigate whether the increase virulence observed with non-Eur variants in 
various populations is caused by differences in virulence of different HPV 16 
variants or is a result of the genetic differences of different populations to 
mount an effective immunological response against a specific HPV 16 
variant. This is because several studies have found the Eur variant to be 
more oncogenic compared to the non-Eur variant in various populations 
(Bokal, et al., 2010; Tu et al., 2006). We could not clarify such phenomenon 
in the current study due to several limitations such as small sample size and 
we did not clone the PCR product prior to sequencing therefore could not 
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Figure 1 Alignment of HPV 16R (Eur), Asian American, Asian, African1 and African2, 
GenBank accession numbers; NC_001526 and AF402678 (AA), AF534061 (As), AF472508 
(Afr1) and AF472509 (Afr2) respectively aligned with LCR sequences from couples; 181, 
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Figure 2 Alignment of HPV 58R, A1, A2, A3, B1, B2, C, D1 and D2, GenBank accession 
number; NC_001443/D90400, HQ339045 (A1), HQ338950 (A2), QH339150 (A3), 
HQ339176 (B1), HQ339309 (B2), HQ339310 (C), HQ338954 (D1) and HQ339312 (D2), 
















Figure 3 Alignment of HPV 53R (P-L) and non prototype-like (non P-L) variants, GenBank 
accession number X74482 and AY949073, alighned with LCR sequences from couples; 308, 
339, 364, 408, 461, 501, 529, 571, 669, 683, 696 and 702.  
 
 
